rizatriptan has been researched along with Abdominal Migraine in 232 studies
rizatriptan: structure given in first source; RN given refers to benzoate
| Excerpt | Relevance | Reference |
|---|---|---|
| "A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation." | 9.15 | Rizatriptan reduces vestibular-induced motion sickness in migraineurs. ( Balaban, CD; Furman, JM; Marcus, DA, 2011) |
| "Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness." | 9.14 | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. ( Furman, JM; Marcus, DA, 2009) |
| "To confirm the efficacy of rizatriptan 10 mg orally disintegrating tablet (ODT) for the elimination of migraine-associated nausea." | 9.13 | Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study. ( Freitag, F; Hamid, MA; Hustad, CM; Ramsey, KE; Rodgers, A; Skobieranda, F; Taylor, FR, 2008) |
| "Ten healthy adult migraineurs (5 migrainous vertigo and 5 migraine without associated vestibular symptoms) with a history of motion sickness were tested in three sessions: a baseline vestibular battery and two motion sickness provocation sessions two hours following randomly ordered blinded pre-treatment with either oral rizatriptan 10 mg or placebo." | 9.12 | Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. ( Furman, JM; Marcus, DA, 2006) |
| "To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack." | 7.71 | Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. ( Goadsby, PJ; Jiang, K; Lines, CR; Lipton, RB; Massiou, H; McCarroll, KA; Pascual, J; Vandormael, K, 2001) |
| "He was recently diagnosed with cluster headaches and was treated with indomethacin, prednisone, butalbital-acetaminophen-caffeine and hydrocodone without relief." | 5.33 | Renal infarction during the use of rizatriptan and zolmitriptan: two case reports. ( Fulton, JA; Hoffman, RS; Kahn, J; Nelson, LS, 2006) |
| "A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation." | 5.15 | Rizatriptan reduces vestibular-induced motion sickness in migraineurs. ( Balaban, CD; Furman, JM; Marcus, DA, 2011) |
| "Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness." | 5.14 | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. ( Furman, JM; Marcus, DA, 2009) |
| " In allodynic patients with moderate-to-severe headache, rizatriptan resulted in greater pain relief compared with ibuprofen." | 5.14 | A comparison of migraine patients with and without allodynic symptoms. ( Kalita, J; Misra, UK; Yadav, RK, 2009) |
| "To confirm the efficacy of rizatriptan 10 mg orally disintegrating tablet (ODT) for the elimination of migraine-associated nausea." | 5.13 | Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study. ( Freitag, F; Hamid, MA; Hustad, CM; Ramsey, KE; Rodgers, A; Skobieranda, F; Taylor, FR, 2008) |
| "Ten healthy adult migraineurs (5 migrainous vertigo and 5 migraine without associated vestibular symptoms) with a history of motion sickness were tested in three sessions: a baseline vestibular battery and two motion sickness provocation sessions two hours following randomly ordered blinded pre-treatment with either oral rizatriptan 10 mg or placebo." | 5.12 | Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. ( Furman, JM; Marcus, DA, 2006) |
| " Identical randomized double-blind studies were conducted comparing the efficacy of rizatriptan 10 mg or placebo administered within 1 h of headache onset, while pain was mild." | 5.12 | Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. ( Cady, R; Hustad, C; Martin, V; Mauskop, A; Ramsey, K; Rodgers, A; Skobieranda, F, 2007) |
| " To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies." | 4.89 | Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies. ( Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Cortelli, P; Curone, M; Omboni, S; Peccarisi, C; Pezzola, D; Tullo, V; Zava, D, 2013) |
| "To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack." | 3.71 | Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. ( Goadsby, PJ; Jiang, K; Lines, CR; Lipton, RB; Massiou, H; McCarroll, KA; Pascual, J; Vandormael, K, 2001) |
| "Headache during migraine attack may recur during a single attack." | 2.82 | [Comparison of triptans, NSAID and combination in migraine attack treatment]. ( Dede, HÖ; Duman, T; Şeydaoğlu, G, 2016) |
| "In six subsequent migraine attacks, each participant received either placebo or Maxalt (10-mg rizatriptan) administered under three information conditions ranging from negative to neutral to positive (told placebo, told Maxalt or placebo, told Maxalt) (N = 459 documented attacks)." | 2.79 | Altered placebo and drug labeling changes the outcome of episodic migraine attacks. ( Burstein, R; Hoaglin, DC; Jakubowski, M; Kam-Hansen, S; Kaptchuk, TJ; Kelley, JM; Kirsch, I, 2014) |
| " Although previous studies have independently compared the efficacy of these agents, contemporaneous data examining both pharmacokinetic (PK) properties and efficacy in parallel have not previously been available." | 2.79 | Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. ( Egan, CG; Mogavero, S; Savi, L, 2014) |
| "Rizatriptan was found more efficacious than conventional therapy in terminating an attack of migraine and its' associated symptoms but looking into the contra-indications, side-effects and cost of the former there has been limitation in its prescription as well as the use." | 2.79 | Clinicopharmacological comparative study of rizatriptan versus conventional therapy in migraine. ( Kushwah, A; Tomar, A, 2014) |
| "Rizatriptan was generally safe and well tolerated in the long-term acute treatment of migraine in pediatric patients aged 12-17 years and demonstrated a consistent treatment effect over time." | 2.78 | Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs. ( Assaid, C; Bachman, R; Ceesay, P; Connor, KM; Dupre, N; Hämäläinen, M; Harper Mozley, L; Hewitt, DJ; Ho, TW; Lewis, D; Lines, C; Mahoney, E; Michelson, D; Pearlman, E; Strickler, N, 2013) |
| "Rizatriptan 10-mg ODT was superior to placebo at all pain end points for treatment of acute migraine in patients using topiramate for migraine prophylaxis." | 2.77 | Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis. ( Cady, RK; Connor, KM; Ge, Y; Ho, TW; Hustad, CM; MacGregor, A; Schaefer, E; Seeburger, JL; Strickler, N; Valade, D; Winner, P; Zhang, Y, 2012) |
| "To evaluate the pharmacokinetic profile and tolerability of single doses of rizatriptan oral disintegrating tablets (ODTs) in pediatric migraineurs." | 2.77 | Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ( Fraser, IP; Han, L; Han, TH; Hreniuk, D; Li, CC; Linder, S; Stoch, SA; Wagner, JA; Winner, P, 2012) |
| "Rizatriptan was also more effective than placebo on most secondary endpoints." | 2.77 | Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial. ( Aurilia, C; Barbanti, P; Bonassi, S; Dall'Armi, V; Egeo, G; Fofi, L; Vanacore, N, 2012) |
| " The trial included a double-blind run-in with weight-based rizatriptan dosing (5 mg for < 40 kg, 10 mg for ≥ 40 kg)." | 2.77 | Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. ( Assaid, C; Bachman, R; Connor, K; Hämäläinen, M; Hewitt, DJ; Ho, TW; Lewis, D; Lines, C; Mahoney, E; Michelson, D; Mozley, LH; Pearlman, E; Strickler, N; Zhang, Y, 2012) |
| "148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2." | 2.76 | A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. ( Ferrari, MD; Lisotto, C; Omboni, S; Pinessi, L; Savi, L; Zanchin, G; Zava, D, 2011) |
| "Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg." | 2.76 | Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. ( Connor, KM; Fan, X; Friedman, D; Ge, Y; Hewitt, D; Ho, T; Hustad, CM; Lasorda, J; Newman, L; Seeburger, JL; Taylor, FR; Zhang, Y, 2011) |
| "Frovatriptan was as effective as rizatriptan in the immediate treatment of menstrually related migraine attacks while showing a favorable sustained effect with a lower rate of migraine recurrence." | 2.76 | Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. ( Ferrari, MD; Lisotto, C; Omboni, S; Pinessi, L; Savi, L; Zanchin, G; Zava, D, 2011) |
| "In the moderate/severe migraine studies of 2068 individuals treated with rizatriptan, 284 (13." | 2.74 | Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. ( Bigal, ME; Ho, TW; Rodgers, A, 2009) |
| "Rizatriptan was preferred by most patients." | 2.74 | Migraine treatment with rizatriptan and almotriptan: a crossover study. ( Bigal, M; Hu, XH; Ng-Mak, DS, 2009) |
| "Acetaminophen has been studied for acute migraine treatment." | 2.73 | Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. ( Diamond, M; Diamond, S; Freitag, F; Janssen, I; Rodgers, A; Skobieranda, F, 2008) |
| "Almotriptan was associated with a significantly lower incidence of triptan-associated AEs in triptan-naïve patients (8." | 2.73 | Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. ( Díez, FI; Straube, A; Zanchin, G, 2007) |
| "Rizatriptan 10 mg was effective for the treatment of ICHD-II menstrual migraine, as measured by 2-h pain relief and 24-h sustained pain relief." | 2.73 | Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. ( Hustad, CM; Loder, E; Mannix, LK; Mueller, L; Nett, R; Ramsey, KE; Rodgers, A; Skobieranda, F, 2007) |
| "Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h." | 2.73 | Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. ( Kalita, J; Misra, UK; Yadav, RK, 2007) |
| "Rizatriptan intake was also checked in all groups of patients at T0, T1, and T2." | 2.73 | Traditional acupuncture in migraine: a controlled, randomized study. ( Coluzzi, F; De Nardin, M; Facco, E; Liguori, A; Mattia, C; Petti, F; Zanette, G, 2008) |
| "Rizatriptan 10 mg was effective for the treatment of menstrual migraine in an early intervention model, as measured by 2-hour pain freedom." | 2.73 | Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies. ( Cady, R; Hustad, CM; Martin, V; Mauskop, A; Ramsey, KE; Rodgers, A; Seidman, LS; Skobieranda, F, 2008) |
| "Rizatriptan 10 mg was superior to placebo for the treatment of PMM, as measured by 2-hour pain relief." | 2.73 | Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. ( Hustad, CM; Mannix, LK; Mueller, L; Nett, R; Ramsey, KE; Rodgers, A; Skobieranda, F, 2008) |
| "Rizatriptan 10 mg was superior to placebo when treating migraine early, while pain is mild, as measured by pain freedom at 2 hours and 24-hour sustained pain freedom." | 2.72 | Efficacy of Rizatriptan 10 mg administered early in a migraine attack. ( Cady, R; Hustad, CM; Martin, V; Mauskop, A; Ramsey, KE; Rodgers, A; Skobieranda, F, 2006) |
| "Trimebutine is an opioid derivative with exclusive action on receptors of the Meissner and Auerbach plexus throughout the digestive tube." | 2.72 | Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. ( Bigal, ME; Filho, PF; Krymchantowski, AV, 2006) |
| " End points included time to pain freedom (length of time from dosing to no pain) and time to onset of pain relief (mean time to onset of pain relief and proportion of patients reporting onset of pain relief at 30 minutes), satisfaction with treatment, and medication preference." | 2.72 | Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study. ( Barlas, S; Bell, CF; Foley, KA; Hu, XH; Solomon, G, 2006) |
| "Rizatriptan dose was 5 mg for those with a body weight of 20 to 39 kg, and 10 mg for those with a body weight of 40 kg or more." | 2.72 | A randomized trial of rizatriptan in migraine attacks in children. ( Ahonen, K; Eerola, M; Hämäläinen, ML; Hoppu, K, 2006) |
| " The effect of study treatment on migraine pain was assessed immediately before dosing and at 0." | 2.72 | Comparative sensitivity of stopwatch methodology and conventional pain assessment measures for detecting early response to triptans in migraine: results of a randomized, open-label pilot study. ( Almas, M; Elkind, A; Mulhern, SA; Olson, N; Sikes, C; Sunshine, A, 2006) |
| "Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine." | 2.71 | Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. ( Allen, C; Christie, S; Göbel, H; Mateos, V; Shivaprakash, M; Vrijens, F, 2003) |
| "Adult migraineurs treated two migraine attacks with either rizatriptan 10-mg standard tablets or rizatriptan 10-mg orally disintegrating tablets in a crossover manner." | 2.71 | Real-world experiences in migraine therapy with rizatriptan. ( Cutrer, FM; Dayno, J; Goldstein, J; Hu, XH; Jamieson, D, 2003) |
| "Migraine is a common, chronic, often disabling neurologic condition that is underdiagnosed and undertreated." | 2.71 | Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. ( Cano Orgaz, A; Ceballos Hernansanz, MA; López-Gil, A; Sanchez Roy, R, 2003) |
| "Rizatriptan was reported to be much better than other drugs by 74." | 2.71 | Rizatriptan RPD for severe migraine in the emergency department--a multicenter study. ( Bokish, N; Dashkovsky, E; Derazon, H; Hay, E; Hussain, A; Kafka, M; Kopelovitch, G; Nassimyan, S; Rodrig, J; Shtibelman, I, 2003) |
| "Patient satisfaction and migraine-specific quality-of-life scores were also significantly better for attacks treated with rizatriptan." | 2.71 | Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting. ( Baos, V; Bertral, C; Caloto, MT; Gerth, WC; Nocea, G; Serrano, A; Torrecilla, M, 2003) |
| "Patients assessed pain severity, migraine-associated symptoms, and functional disability at 0." | 2.71 | Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. ( Battisti, WP; Johnson-Pratt, L; Kolodny, A; Polis, A; Skobieranda, F, 2004) |
| "Rizatriptan is an effective and fast acting drug for the acute treatment of migraine." | 2.71 | Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. ( Bigal, ME; Krymchantowski, AV, 2004) |
| "Rizatriptan 5 mg was well tolerated in both the studies, with an adverse event profile not significantly different from that of placebo or standard care." | 2.71 | Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. ( Cady, R; Klipfel, M; Lewis, D; McCarroll, K; Nett, R; Peng, Y; Strohmaier, K; Visser, WH; Winner, P, 2004) |
| "Rizatriptan was significantly more effective than non-triptans in the relief of migraine headaches for patients obtaining prescribed migraine medications from a retail pharmacy." | 2.71 | Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study. ( Adelman, J; Cady, R; Diamond, M; Hu, XH; Martin, V; Sajjan, S, 2004) |
| "Fourteen patients suffering from migraine without aura were monitored to evaluate mean flow velocity changes on both middle cerebral arteries during migraine attack 30 min before and 120 min after oral administration of rizatriptan 10mg." | 2.71 | Rizatriptan does not change cerebral blood flow velocity during migraine attacks. ( Bellini, G; Bonanni, E; Gori, S; Iudice, A; Manca, L; Morelli, N; Murri, L; Orlandi, G, 2005) |
| "Rizatriptan was twice as likely to return patients to normal function than usual nontriptan therapy after adjusting for confounding factors (adjusted hazard ratio, 2." | 2.71 | Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference. ( García-Moncó, C; López-Gil, A; Pascual, J; Roig, C; Yusta Izquierdo, A, 2005) |
| "Rizatriptan was proved effective in treating migraine patients accompanied by tension headache-like symptoms." | 2.71 | Clinical efficacy of rizatriptan for patients with migraine: efficacy of drug therapy for migraine accompanied by tension headache-like symptoms, focusing on neck stiffness. ( Kitagawa, Y; Okuma, H; Takagi, S, 2005) |
| "In conclusion, migraine therapy that provides rapid, complete, and sustained pain relief, with restoration of functional ability, has the most beneficial impact on short-term health-related quality of life for migraineurs." | 2.70 | Determinants of migraine-specific quality of life. ( Allen, C; Davies, G; Kramer, M; Lipton, R; Santanello, NC, 2002) |
| "After treating three migraine attacks, the proportion of patients fully or very satisfied with rizatriptan was over 79% for all the domains explored." | 2.70 | [Satisfaction and recovery of normal activity with rizatriptan 10 mg. Results from the open, prospective, observational 4M study]. ( López Rodríguez, I; López-Gil, A; Mateos, V; Roig, C, 2002) |
| "Rizatriptan has a favorable side effect profile, and, provided contraindications are observed, severe adverse cardiovascular complications are extremely unlikely." | 2.70 | Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes. ( Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V, 2001) |
| "Rizatriptan was also superior to sumatriptan in terms of the proportions of patients with no nausea, phonophobia or photophobia, and patients with normal function 2 h after treatment intake (p < 0." | 2.70 | Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. ( Allen, C; Bussone, G; Hernandez, JF; Pascual, J; Patel, K; Vrijens, F, 2001) |
| "Rizatriptan is a selective 5-HT1B/1D receptor agonist for the acute treatment of migraine." | 2.70 | Long-term efficacy and tolerability of rizatriptan wafers in migraine. ( Ahrens, S; Cady, R; Crawford, G; Getson, A; Hairwassers, D; Lines, C; Visser, WH, 2001) |
| "Rizatriptan ODT is an orally disintegrating formulation of rizatriptan, a selective 5-HT1B/1D receptor agonist." | 2.70 | Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. ( Bohidar, N; Boyle, D; Brandes, JL; Guerra, F; Johnson-Pratt, L; Kolodny, A; Loder, E; Santanello, N; Silberstein, S; Skobieranda, F; Wang, L, 2001) |
| "Rizatriptan 5 mg was well tolerated." | 2.70 | Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. ( Ahrens, S; Evans, JK; Jiang, K; Lewis, D; Visser, WH; Winner, P, 2002) |
| "Rizatriptan is an effective and fast acting drug for the acute treatment of migraine." | 2.70 | Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. ( Barbosa, JS; Krymchantowski, AV, 2002) |
| "Rizatriptan 5 mg was well tolerated and 67% of the patients experienced headache relief 2 hours postdose." | 2.69 | Pharmacokinetics of rizatriptan tablets during and between migraine attacks. ( Brucker, MJ; Carides, AD; Cutler, NR; Goldberg, MR; Jhee, SS; Kramer, MS; Majumdar, AK; Matzura-Wolfe, D; McLaughlin, D; Reines, SA, 1999) |
| "Rizatriptan is a novel 5-HT1B/1D agonist which is rapidly absorbed after oral administration." | 2.69 | Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. ( Block, G; Cutler, N; Gross, M; Jiang, K; Reines, S; Smith, B; Teall, J; Tuchman, M; Willoughby, E, 1998) |
| "Rizatriptan is a potent and rapidly absorbed 5-HT1B/1D receptor agonist." | 2.69 | A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. ( Amaraneni, PG; Feighner, J; Getson, A; Kramer, MS; Matzura-Wolfe, D; McHugh, W; Polis, A; Reines, SA; Silberstein, S; Solbach, MP, 1998) |
| "rizatriptan (0." | 2.69 | Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ( Blum, RA; Brucker, MJ; Ermlich, SJ; Goldberg, MR; Lee, Y; McLoughlin, DA; Olah, TV; Rogers, JD; Sterrett, AT; Zhao, J, 1998) |
| "Effective, well-tolerated migraine therapy with rapid onset of relief could decrease work and productivity losses." | 2.69 | Validation of a migraine work and productivity loss questionnaire for use in migraine studies. ( Block, GA; Davies, GM; Gerth, W; Lerner, D; Santanello, N, 1999) |
| "Rizatriptan is a potent, highly selective 5HT1B/1D agonist with rapid onset of action for acute treatment of migraine." | 2.69 | Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. ( Ahrens, SP; Block, GA; Farmer, MV; Jiang, K; Visser, WH; Williams, DL; Willoughby, E, 1999) |
| "Rizatriptan was more effective than naratriptan." | 2.69 | Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. ( Allen, C; Bomhof, M; Legg, N; Patel, K; Paz, J; Vandormael, K, 1999) |
| "Zolmitriptan was the only triptan that decreased temporal artery diameter significantly (by 12% +/- 3%, P < ." | 2.69 | Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. ( de Hoon, JN; Struijker-Boudier, HA; Troost, J; Van Bortel, LM; Willigers, JM, 2000) |
| " Headache severity, functional disability, and associated migraine symptoms were measured immediately before dosing and at regular intervals up to 4 hours after the dose." | 2.69 | Within-patient consistency of response of rizatriptan for treating migraine. ( Dahlöf, CG; Ferrari, MD; Kramer, MS; Lines, CR; Lipton, RB; McCarroll, KA, 2000) |
| "in patients treating four separate migraine attacks." | 2.69 | Work and productivity loss in the rizatriptan multiple attack study. ( Carides, GW; Dasbach, EJ; Gerth, WC; Pigeon, JG; Santanello, NC, 2000) |
| "Rizatriptan (MK-462) is a new 5-hydroxytryptamine1D (serotonin1D; 5-HT1D) receptor agonist for the acute treatment of migraine that has improved pharmacokinetic properties compared with sumatriptan succinate." | 2.68 | Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. ( Ferrari, MD; Jiang, K; Lines, CR; Reines, SA; Terwindt, GM; Visser, WH, 1996) |
| "Rizatriptan (MK-462) is a potent 5HTID receptor agonist." | 2.68 | Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. ( Block, G; Ferrari, MD; Gijsman, H; Kramer, MS; Matzura-Wolfe, D; Polis, A; Sargent, J; Teall, J; Tuchman, M, 1997) |
| "A validated migraine-specific questionnaire (24-h Migraine Quality of Life Questionnaire: 24-h MQoLQ) was used to assess the impact of migraine and migraine therapy on health-related quality of life during an acute migraine attack." | 2.68 | Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. ( Block, GA; Hartmaier, SL; Kramer, MS; Polis, AB; Santanello, NC; Silberstein, SD, 1997) |
| "Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours)." | 2.53 | Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. ( Allais, G; Benedetto, C, 2016) |
| "Migraine is a neurological disorder resulting in large socioeconomic burden." | 2.53 | Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. ( Han, W; Li, M; Wang, J; Xu, H, 2016) |
| "Rizatriptan was approved by Food and Drug Administration (FDA) (USA) for children and adolescents of 6-17 years." | 2.52 | Oral triptans in children and adolescents: an update. ( Sakai, F, 2015) |
| "Studies on the acute treatment of migraine in children and adolescents are rare and difficult to design." | 2.49 | The efficacy of triptans in childhood and adolescence migraine. ( Evers, S, 2013) |
| "Rizatriptan has shown the quickest onset of action, both in controlled studies and in the different metaanalyses, which translates in high efficacy levels at two hours." | 2.49 | [Rizatriptan: experience after 15 years of clinical use]. ( Alvarez-Escudero, R; Pascual, J; Ramón-Carbajo, C, 2013) |
| "Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family." | 2.48 | Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "Rizatriptan 10 mg was superior to placebo in achieving TMF at 2 hours post-dose across all treatment paradigms." | 2.47 | Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database. ( Cady, RK; Ho, TW; Hustad, CM; Martin, VT; Ramsey, KE; Rodgers, AJ; Winner, P, 2011) |
| "Rizatriptan 10 mg has demonstrated, in a head-to-head study, higher response rates and a more rapid onset of action than sumatriptan 100 mg, together with a favorable tolerability profile." | 2.46 | Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis. ( Göbel, H, 2010) |
| "We then briefly discuss migraine treatment behavior issues, including early treatment and adherence to treatment." | 2.45 | Acute migraine treatment with rizatriptan in real world settings - focusing on treatment strategy, effectiveness, and behavior. ( Bigal, ME; Cady, R; Hu, H; Kurth, T; Santanello, N, 2009) |
| "Menstrually related migraine (MRM) headache is common in women and associated with substantial disability." | 2.44 | Acute treatment and prevention of menstrually related migraine headache: evidence-based review. ( Davenport, WJ; Dodick, D; Pringsheim, T, 2008) |
| "Rizatriptan was somewhat less costly and more effective than sumatriptan." | 2.43 | Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. ( Hay, JW; Zhang, L, 2005) |
| "The management of pediatric migraine requires a balance of biobehavioral measures coupled with agents for acute treatment and, if needed, daily preventive medicines." | 2.43 | The treatment of pediatric migraine. ( Lewis, DW; Sowell, M; Winner, P; Yonker, M, 2005) |
| "Rizatriptan is a selective agonist of the 5-hydroxytryptophan(1B/1D )receptors, with proven superiority over placebo, ergotamine and selected oral triptans, demonstrating a good profile of safety and tolerability." | 2.43 | Rizatriptan in migraine. ( Bigal, ME; Krymchantowski, AV, 2005) |
| "Rizatriptan was cost effective compared with usual care with an incremental cost per quality-adjusted life-year (QALY) gained of 31,845 Can dollars (2002 values) and an incremental cost per additional attack aborted of 49." | 2.43 | Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine. ( Foster, RH; McCormack, PL, 2005) |
| "Migraine is a common, frequently incapacitating, headache disorder that imposes a substantial burden on both the individual patient and society." | 2.42 | Newer formulations of the triptans: advances in migraine management. ( Gawel, M; Gladstone, JP, 2003) |
| "Naratriptan is an effective and well-tolerated treatment for acute attacks of migraine." | 2.42 | Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. ( Ashcroft, DM; Millson, D, 2004) |
| "Rizatriptan is a second-generation triptan marketed as 5 and 10 mg tablets and rapidly disintegrating wafer formulations." | 2.42 | A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine. ( Pascual, J, 2004) |
| "Rizatriptan is a highly potent, selective serotonin 5-HT(1B/1D)-receptor agonist." | 2.42 | [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. ( Aijima, H; Ikemoto, F; Natsumeda, Y; Toru, T, 2004) |
| "Migraine is a common disorder with a prevalence of 9-10% in Hungary." | 2.41 | [Treatment of migraine in patients with hypertension and ischemic heart disease]. ( Csiba, L; Ficzere, A, 2002) |
| "Rizatriptan is an orally active serotonin 5-HT(1) receptor agonist that potently and selectively binds to 5-HT(1B/1D) subtypes." | 2.41 | Spotlight on rizatriptan in migraine. ( Jarvis, B; Wellington, K, 2002) |
| "Rizatriptan 10 mg was generally superior to sumatriptan on a measure of time-to-pain-relief within 2 h, where pain relief was defined as a reduction of pain to mild or none (odds ratio for rizatriptan versus sumatriptan 100 mg = 1." | 2.41 | Rizatriptan: pharmacological differences from sumatriptan and clinical results. ( Lines, CR; McCarroll, KA; Visser, WH, 2001) |
| "Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies." | 2.41 | Newer intranasal migraine medications. ( Logemann, CD; Rankin, LM, 2000) |
| "Current theories on the etiology of migraine headache suggest that it is a neurovascular disorder (i." | 2.41 | Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan. ( Goadsby, PJ; Hargreaves, RJ, 2000) |
| "Rizatriptan is a new, selective 5-HT1B/1D receptor agonist that is effective for treatment of migraine." | 2.41 | The use of rizatriptan in the treatment of acute, multiple migraine attacks. ( Saper, JR, 2000) |
| "Even a migraine of moderate intensity can impair function and productivity, which emphasizes the importance of therapy that achieves complete, as opposed to partial, pain relief." | 2.41 | Impact of migraine and migraine therapy on productivity and quality of life. ( Santanello, N; Solomon, GD, 2000) |
| "Rizatriptan 10 mg was also more effective than rizatriptan 5 mg, with a significant superiority at 2 h on all measures except for elimination of nausea." | 2.41 | Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. ( Ferrari, MD; Lines, CR; Loder, E; McCarroll, KA, 2001) |
| "Oral rizatriptan 10 mg was more effective than oral sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures of pain-free response at 2 hours, symptom-free response at 2 hours, and 24-hour sustained pain-free response." | 2.41 | Comparison of rizatriptan and other triptans on stringent measures of efficacy. ( Adelman, JU; Diener, HC; Ferrari, MD; Lines, CR; Lipton, RB; McCarroll, KA; Vandormael, K, 2001) |
| "Rizatriptan is a potent, selective 5-HT1B/1D receptor agonist shown to be fast, effective and well tolerated in the acute treatment of migraine." | 2.41 | Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons. ( Gerth, WC; Mannix, LK; McCarroll, KA; Santanello, NC; Vandormael, K; Zhang, Q, 2001) |
| "There exist increasing options for migraine treatment that may further improve the clinical effects of the older and newer triptans through early treatment of migraine at the stages of mild migraine pain, or even during the prodromal phase of the attack." | 2.41 | Acute treatment of migraine and the role of triptans. ( Freitag, FG, 2001) |
| "Rizatriptan is an orally active serotonin 5-HT(1) receptor agonist that potently and selectively binds to 5-HT(1B/1D) subtypes." | 2.41 | Rizatriptan: an update of its use in the management of migraine. ( Plosker, GL; Wellington, K, 2002) |
| "Rizatriptan is an orally active serotonin 5-HT1 receptor agonist selective for the 5-HT(1B/1D) subtypes." | 2.40 | Rizatriptan: a review of its efficacy in the management of migraine. ( Dooley, M; Faulds, D, 1999) |
| "Thus sumatriptan has become the de facto gold standard and will be thus employed here." | 2.40 | The scientific basis of medication choice in symptomatic migraine treatment. ( Goadsby, PJ, 1999) |
| "Rizatriptan is a selective 5-hydroxytriptamine1B/1D receptor agonist that was launched in 1998 for the acute treatment of migraine in adults." | 2.40 | Rizatriptan in the treatment of migraine. ( Dahlof, CG; Lines, CR; Rapoport, AM; Sheftell, FD, 1999) |
| "The significant anti-migraine efficacy of RB-SLNs was corroborated through the pharmacodynamic studies on adult male Swiss albino mice." | 1.46 | Multivariate Optimization of Rizatriptan Benzoate-Loaded Solid Lipid Nanoparticles for Brain Targeting and Migraine Management. ( Girotra, P; Singh, SK, 2017) |
| "Oral contraceptive-induced menstrual migraine (OCMM) is a particularly severe form of migraine triggered by the cyclic hormone withdrawal." | 1.39 | Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies. ( Allais, G; Benedetto, C; Bussone, G; Omboni, S; Pezzola, D; Tullo, V; Zava, D, 2013) |
| "Based on models of migraine pathology, several inflammatory molecules including protons are thought to facilitate sensitization and activation of trigeminal nociceptive neurons and stimulate CGRP secretion." | 1.39 | Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment. ( Durham, PL; Masterson, CG, 2013) |
| "Triptans were used as a model, because migraine is common in children, and is the only indication for triptans." | 1.37 | Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007. ( Airaksinen, M; Hoppu, K; Kaukonen, AM; Klaukka, T; Lindkvist, J, 2011) |
| "To evaluate the migraine triggers in consecutive patients and correlate these with demographic and clinical variables." | 1.36 | A study of triggers of migraine in India. ( Kalita, J; Misra, UK; Yadav, RK, 2010) |
| "Normalized ASL images acquired during migraine attack showed significant relative hypoperfusion in the bilateral median thalamic areas including hypothalamus and significant relative hyperperfusion in the frontal cortex compared to images acquired during the migraine-free state." | 1.36 | Arterial spin-labeled MRI study of migraine attacks treated with rizatriptan. ( Araki, N; Ito, Y; Kato, Y; Matsuda, H; Suzuki, C, 2010) |
| "Significantly, more patients taking rizatriptan achieved both PR and PF within 2 h after dosing than other oral triptans." | 1.34 | Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. ( Chen, Y; Hu, XH; Ma, L; Ng-Mak, DS; Solomon, G, 2007) |
| "Chronic migraine (CM) is a common disorder, affecting 2% to 3% of the general population." | 1.34 | Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. ( Cavalheiro, EA; Naffah-Mazzacoratti, Mda G; Peres, MF; Senne Soares, CA; Vieira, DS; Zukerman, E, 2007) |
| "Eletriptan 40 mg also was found to have the lowest total triptan cost to successfully treat 100 patients." | 1.33 | Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. ( Healey, PJ; Mullins, CD; Perfetto, EM; Subedi, PR; Weis, KA, 2005) |
| "Oral rizatriptan 10 mg was compared with other oral triptans (i." | 1.33 | An economic evaluation of rizatriptan in the treatment of migraine. ( Desjardins, B; Ferko, N; Gawel, M; Grima, D; Thompson, M, 2005) |
| " Seven 5-HT(1B/D) agonists have been approved in Germany with more than 20 dosage forms." | 1.33 | Company reference estimates for productivity loss due to migraine and productivity gains using rizatriptan 10 mg in Germany. ( Diener, HC; Katsarava, Z; Krobot, KJ; Liedert, B; Limmroth, V; Yoon, MS, 2006) |
| "He was recently diagnosed with cluster headaches and was treated with indomethacin, prednisone, butalbital-acetaminophen-caffeine and hydrocodone without relief." | 1.33 | Renal infarction during the use of rizatriptan and zolmitriptan: two case reports. ( Fulton, JA; Hoffman, RS; Kahn, J; Nelson, LS, 2006) |
| "Rizatriptan ODT was preferred by 68." | 1.33 | Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches. ( Billups, SJ; Carroll, N; Delate, T; Gershovich, OE; Hoffman, CK, 2006) |
| "Rizatriptan was discontinued, the patient recovered without sequelae from both episodes of TIA." | 1.33 | Transient ischemic attack after rizatriptan administration in a liver transplant recipient: a case report. ( Adani, GL; Baccarani, U; Bresadola, F; Curro, G; Lorenzin, D, 2006) |
| "Almotriptan 12." | 1.32 | Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. ( Reeder, CE; Williams, P, 2003) |
| "For many migraine patients, triptan therapy provides complete pain relief in some attacks but not in others." | 1.32 | Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. ( Burstein, R; Collins, B; Jakubowski, M, 2004) |
| "To evaluate changes in migraine-related productivity and non-workplace impairment associated with a migraine intervention program from the employer perspective." | 1.32 | The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. ( Burke, TA; Laínez, MJ; Vicente-Herrero, T, 2004) |
| "In the treatment of acute migraine, patients need a drug that provides convenient dosing and consistent effectiveness." | 1.31 | Rizatriptan. Convenience and consistency. ( Evans, RW, 2000) |
| "Data from most clinical trials of migraine drugs use standard endpoints of level of pain relief at 2 hours and percentage of patients who are pain free at 2 hours." | 1.31 | Evaluating the efficacy of migraine therapy. ( Chawluk, JB, 2000) |
| "In direct head-to-head comparative clinical trials, oral rizatriptan 10 mg enabled more migraine sufferers to function normally at 2 h after dosing than oral sumatriptan, naratriptan, and zolmitriptan." | 1.31 | Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. ( Bussone, G; D'Amico, D; Gerth, W; Lines, CR; McCarroll, KA, 2002) |
| "Rizatriptan 10 mg was equally effective in menstrual and nonmenstrual migraine attacks regardless of the definition used." | 1.31 | Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. ( Lines, CR; Massiou, H; McCarroll, KA; Silberstein, SD, 2002) |
| " The absorption of rizatriptan was approximately 90%, but it experienced a moderate first-pass effect, resulting in a bioavailability estimate of 47%." | 1.31 | Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ( Chavez-Eng, C; Cheng, H; Ellis, JD; Geer, LA; Guiblin, AR; Halpin, RA; Liu, L; Matuszewski, BK; Rogers, JD; Varga, SL; Vyas, KP, 2000) |
| " In all women, rizatriptan was as effective in treating menstrual as well as nonmenstrual migraine: 68% of 139 patients taking rizatriptan 10 mg with a menstrually associated migraine had pain relief at 2 hours after dosing compared with 69% of 393 patients with nonmenstrually associated attacks (test of menstrual association = nonsignificant; the analysis had 80% power to detect a difference of six percentage points between groups)." | 1.31 | Rizatriptan in the treatment of menstrual migraine. ( Johnson-Pratt, L; Le Jeunne, C; Lines, CR; Massiou, H; McCarroll, KA; Silberstein, SD, 2000) |
| " In early clinical trials, rizatriptan was shown to have good bioavailability and favorable effects on quality of life." | 1.31 | Rizatriptan versus usual care in long-term treatment of migraine. ( Silberstein, SD, 2000) |
| "Within 2 hours after initial dosing of rizatriptan, significantly more patients taking either the rizatriptan tablet or the rizatriptan wafer reported onset of pain relief, had become largely symptom free, and were able to resume usual activities compared with their baseline responses to nontriptans (P < 0." | 1.31 | Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study. ( Berger, M; Frishberg, B; Hu, XH; Markson, L; Solomon, S, 2001) |
| "A total of 1919 migraineurs with 3450 migraine attack episodes were evaluated, of which 1369 episodes were early use and 2081 delayed use." | 1.31 | Treatment of migraine with rizatriptan: when to take the medication. ( Berger, ML; Cowan, R; Hu, XH; Markson, LE; Raskin, NH, 2002) |
| "Rizatriptan was associated with significantly lower triptan tablet use and additional medication use per attack than the other triptans." | 1.31 | Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. ( Fité, B; López-Gil, A; Pascual, J, 2002) |
| "Rizatriptan therefore has central activity which may contribute to its efficacy against migraine headache." | 1.30 | Rizatriptan has central antinociceptive effects against durally evoked responses. ( Cumberbatch, MJ; Hargreaves, RJ; Hill, RG, 1997) |
| "The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting from coronary artery constriction." | 1.30 | Coronary side-effect potential of current and prospective antimigraine drugs. ( Bax, WA; Ferrari, MD; MaassenVanDenBrink, A; Reekers, M; Saxena, PR, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (9.91) | 18.2507 |
| 2000's | 168 (72.41) | 29.6817 |
| 2010's | 39 (16.81) | 24.3611 |
| 2020's | 2 (0.86) | 2.80 |
| Authors | Studies |
|---|---|
| Filla, SA | 1 |
| Winter, MA | 1 |
| Johnson, KW | 1 |
| Bleakman, D | 1 |
| Bell, MG | 1 |
| Bleisch, TJ | 1 |
| Castaño, AM | 1 |
| Clemens-Smith, A | 1 |
| del Prado, M | 1 |
| Dieckman, DK | 1 |
| Dominguez, E | 1 |
| Escribano, A | 1 |
| Ho, KH | 1 |
| Hudziak, KJ | 1 |
| Katofiasc, MA | 1 |
| Martinez-Perez, JA | 1 |
| Mateo, A | 1 |
| Mathes, BM | 1 |
| Mattiuz, EL | 1 |
| Ogden, AM | 1 |
| Phebus, LA | 1 |
| Stack, DR | 1 |
| Stratford, RE | 1 |
| Ornstein, PL | 1 |
| Bell, IM | 1 |
| Chanchlani, R | 1 |
| Agrawal, A | 1 |
| Janjua, D | 1 |
| Hafsa, SN | 1 |
| Amundsen, S | 1 |
| Nordeng, H | 1 |
| Fuskevåg, OM | 1 |
| Nordmo, E | 1 |
| Sager, G | 1 |
| Spigset, O | 1 |
| Hansen, E | 1 |
| Zech, N | 1 |
| Meissner, K | 1 |
| Dieringer, TD | 1 |
| Crossland, DM | 1 |
| Mahl, TC | 1 |
| Allais, G | 4 |
| Tullo, V | 2 |
| Omboni, S | 4 |
| Pezzola, D | 2 |
| Zava, D | 5 |
| Benedetto, C | 3 |
| Bussone, G | 4 |
| Barbanti, P | 2 |
| Cortelli, P | 1 |
| Curone, M | 1 |
| Peccarisi, C | 1 |
| Evers, S | 2 |
| Ramón-Carbajo, C | 1 |
| Alvarez-Escudero, R | 1 |
| Pascual, J | 10 |
| Lisotto, C | 3 |
| Guidotti, M | 1 |
| Savi, L | 4 |
| Cui, XP | 1 |
| Ye, JX | 1 |
| Lin, H | 1 |
| Mu, JS | 1 |
| Lin, M | 1 |
| Kam-Hansen, S | 1 |
| Jakubowski, M | 2 |
| Kelley, JM | 1 |
| Kirsch, I | 1 |
| Hoaglin, DC | 1 |
| Kaptchuk, TJ | 1 |
| Burstein, R | 2 |
| Bingel, U | 1 |
| Mogavero, S | 1 |
| Egan, CG | 1 |
| Tokuoka, K | 1 |
| Takayanagi, R | 1 |
| Suzuki, Y | 1 |
| Watanabe, M | 1 |
| Kitagawa, Y | 2 |
| Yamada, Y | 1 |
| Yao, G | 1 |
| Han, X | 1 |
| Hao, T | 1 |
| Huang, Q | 1 |
| Yu, T | 1 |
| Sakai, F | 3 |
| Kushwah, A | 1 |
| Tomar, A | 1 |
| Bhagawati, ST | 1 |
| Chonkar, AD | 1 |
| Dengale, SJ | 1 |
| Reddy, SM | 1 |
| Bhat, K | 1 |
| Girotra, P | 1 |
| Singh, SK | 1 |
| Duman, T | 1 |
| Dede, HÖ | 1 |
| Şeydaoğlu, G | 1 |
| Xu, H | 1 |
| Han, W | 1 |
| Wang, J | 1 |
| Li, M | 1 |
| O'Quinn, S | 1 |
| Mansbach, H | 1 |
| Salonen, R | 1 |
| Freitag, F | 2 |
| Diamond, M | 2 |
| Diamond, S | 1 |
| Janssen, I | 1 |
| Rodgers, A | 11 |
| Skobieranda, F | 10 |
| Garg, T | 1 |
| Jain, S | 1 |
| Singh, HP | 1 |
| Sharma, A | 1 |
| Tiwary, AK | 1 |
| Hargreaves, RJ | 7 |
| Lines, CR | 13 |
| Rapoport, AM | 3 |
| Ho, TW | 9 |
| Sheftell, FD | 3 |
| Hu, H | 1 |
| Kurth, T | 1 |
| Cady, R | 8 |
| Santanello, N | 5 |
| Bigal, ME | 6 |
| Fan, X | 2 |
| Winner, P | 7 |
| Shapiro, RE | 1 |
| Ng-Mak, DS | 2 |
| Hu, XH | 8 |
| Bigal, M | 1 |
| Cady, RK | 4 |
| Martin, VT | 2 |
| Géraud, G | 1 |
| Zhang, Y | 4 |
| Ho, AP | 1 |
| Hustad, CM | 10 |
| Ho, TP | 1 |
| Connor, KM | 5 |
| Ramsey, KE | 8 |
| Evans, RW | 1 |
| Chawluk, JB | 1 |
| Jamieson, DG | 1 |
| Furman, JM | 3 |
| Marcus, DA | 4 |
| Vause, CV | 1 |
| Durham, PL | 2 |
| Yadav, RK | 3 |
| Kalita, J | 3 |
| Misra, UK | 3 |
| Alkhatib, AA | 1 |
| Gangotena, F | 1 |
| Peterson, KA | 1 |
| Göbel, H | 4 |
| Kato, Y | 1 |
| Araki, N | 1 |
| Matsuda, H | 1 |
| Ito, Y | 1 |
| Suzuki, C | 1 |
| Zanchin, G | 4 |
| Ferrari, MD | 11 |
| Pinessi, L | 2 |
| Balaban, CD | 1 |
| Rodgers, AJ | 1 |
| Aurora, SK | 1 |
| Loeys, T | 1 |
| Ashina, M | 2 |
| Jones, C | 1 |
| Giezek, H | 1 |
| Massaad, R | 2 |
| Williams-Diaz, A | 1 |
| Lines, C | 9 |
| Seeburger, JL | 2 |
| Taylor, FR | 2 |
| Friedman, D | 1 |
| Newman, L | 1 |
| Ge, Y | 2 |
| Lasorda, J | 1 |
| Hewitt, D | 1 |
| Ho, T | 1 |
| Lindkvist, J | 1 |
| Airaksinen, M | 1 |
| Kaukonen, AM | 1 |
| Klaukka, T | 1 |
| Hoppu, K | 2 |
| MacGregor, A | 1 |
| Valade, D | 1 |
| Strickler, N | 3 |
| Schaefer, E | 1 |
| Fraser, IP | 1 |
| Han, L | 1 |
| Han, TH | 1 |
| Li, CC | 1 |
| Hreniuk, D | 1 |
| Stoch, SA | 1 |
| Wagner, JA | 1 |
| Linder, S | 1 |
| Derry, CJ | 1 |
| Derry, S | 1 |
| Moore, RA | 2 |
| Fofi, L | 1 |
| Dall'Armi, V | 1 |
| Aurilia, C | 1 |
| Egeo, G | 1 |
| Vanacore, N | 1 |
| Bonassi, S | 1 |
| Pearlman, E | 2 |
| Lewis, D | 4 |
| Hämäläinen, M | 2 |
| Connor, K | 1 |
| Michelson, D | 2 |
| Assaid, C | 2 |
| Mozley, LH | 1 |
| Bachman, R | 2 |
| Mahoney, E | 2 |
| Hewitt, DJ | 2 |
| Ceesay, P | 1 |
| Harper Mozley, L | 1 |
| Dupre, N | 1 |
| Fernandez-Atutxa, A | 1 |
| Vergara, M | 1 |
| Gil, M | 1 |
| Dalmau, B | 1 |
| Miquel, M | 1 |
| Sanchez-Delgado, J | 1 |
| Casas, M | 1 |
| Masterson, CG | 1 |
| Tepper, SJ | 1 |
| Ficzere, A | 1 |
| Csiba, L | 1 |
| Login, IS | 1 |
| Rieder, MJ | 1 |
| Wellington, K | 2 |
| Jarvis, B | 1 |
| D'Amico, D | 1 |
| McCarroll, KA | 9 |
| Gerth, W | 2 |
| Tfelt-Hansen, P | 5 |
| McCarroll, K | 5 |
| Santanello, NC | 4 |
| Davies, G | 1 |
| Allen, C | 9 |
| Kramer, M | 1 |
| Lipton, R | 2 |
| Silberstein, SD | 5 |
| Massiou, H | 3 |
| Maizels, M | 1 |
| Visser, WH | 6 |
| Christie, S | 1 |
| Mateos, V | 2 |
| Vrijens, F | 3 |
| Shivaprakash, M | 1 |
| Roig, C | 2 |
| López Rodríguez, I | 1 |
| López-Gil, A | 5 |
| Jamieson, D | 1 |
| Cutrer, FM | 1 |
| Goldstein, J | 1 |
| Dayno, J | 2 |
| Adelman, JU | 3 |
| Lewit, EJ | 1 |
| Ceballos Hernansanz, MA | 1 |
| Sanchez Roy, R | 1 |
| Cano Orgaz, A | 1 |
| Létienne, R | 1 |
| Verscheure, Y | 1 |
| John, GW | 1 |
| Gladstone, JP | 1 |
| Gawel, M | 3 |
| Hay, E | 1 |
| Rodrig, J | 1 |
| Hussain, A | 1 |
| Derazon, H | 1 |
| Kopelovitch, G | 1 |
| Dashkovsky, E | 1 |
| Bokish, N | 1 |
| Kafka, M | 1 |
| Shtibelman, I | 1 |
| Nassimyan, S | 1 |
| Major, PW | 1 |
| Grubisa, HS | 1 |
| Thie, NM | 1 |
| Baos, V | 1 |
| Serrano, A | 1 |
| Torrecilla, M | 1 |
| Bertral, C | 1 |
| Caloto, MT | 1 |
| Nocea, G | 1 |
| Gerth, WC | 4 |
| Williams, P | 2 |
| Reeder, CE | 1 |
| Collins, B | 1 |
| Sarma, S | 1 |
| Ashcroft, DM | 1 |
| Millson, D | 1 |
| Iizuka, T | 1 |
| Ikemoto, F | 1 |
| Toru, T | 1 |
| Aijima, H | 1 |
| Natsumeda, Y | 1 |
| Kolodny, A | 2 |
| Polis, A | 3 |
| Battisti, WP | 1 |
| Johnson-Pratt, L | 3 |
| Krymchantowski, AV | 4 |
| Goadsby, PJ | 7 |
| Dodick, DW | 1 |
| McCrory, DC | 1 |
| Vitols, S | 1 |
| Vetr, A | 1 |
| Tomson, T | 1 |
| Strohmaier, K | 1 |
| Klipfel, M | 1 |
| Peng, Y | 1 |
| Nett, R | 3 |
| Martin, V | 4 |
| Adelman, J | 1 |
| Sajjan, S | 1 |
| Vicente-Herrero, T | 1 |
| Burke, TA | 1 |
| Laínez, MJ | 2 |
| Nakashima, K | 1 |
| Takeshima, T | 1 |
| Kowa, H | 1 |
| Igarashi, H | 1 |
| Morillo, LE | 2 |
| Cutler, NR | 2 |
| Jhee, SS | 1 |
| Majumdar, AK | 1 |
| McLaughlin, D | 1 |
| Brucker, MJ | 2 |
| Carides, AD | 1 |
| Kramer, MS | 5 |
| Matzura-Wolfe, D | 3 |
| Reines, SA | 4 |
| Goldberg, MR | 2 |
| Muñoz, P | 1 |
| Gori, S | 2 |
| Morelli, N | 2 |
| Bellini, G | 1 |
| Bonanni, E | 1 |
| Manca, L | 1 |
| Orlandi, G | 1 |
| Iudice, A | 2 |
| Murri, L | 2 |
| Mullins, CD | 1 |
| Weis, KA | 1 |
| Perfetto, EM | 1 |
| Subedi, PR | 1 |
| Healey, PJ | 1 |
| Vollono, C | 1 |
| Capuano, A | 1 |
| Mei, D | 1 |
| Ferraro, D | 1 |
| Pierguidi, L | 1 |
| Evangelista, M | 1 |
| Di Trapani, G | 1 |
| Zhang, L | 1 |
| Hay, JW | 1 |
| Lewis, DW | 1 |
| Yonker, M | 1 |
| Sowell, M | 1 |
| Thompson, M | 1 |
| Desjardins, B | 1 |
| Ferko, N | 1 |
| Grima, D | 1 |
| García-Moncó, C | 1 |
| Yusta Izquierdo, A | 1 |
| McCormack, PL | 1 |
| Foster, RH | 1 |
| Okuma, H | 1 |
| Takagi, S | 1 |
| Kinge, E | 1 |
| Rao, NA | 1 |
| Lis, K | 1 |
| Sarchielli, P | 1 |
| Pini, LA | 1 |
| Alberti, A | 1 |
| Maggioni, F | 1 |
| Rossi, C | 1 |
| Floridi, A | 1 |
| Calabresi, P | 1 |
| Yoon, MS | 1 |
| Katsarava, Z | 1 |
| Liedert, B | 1 |
| Krobot, KJ | 1 |
| Diener, HC | 3 |
| Limmroth, V | 1 |
| Cuvellier, JC | 1 |
| Joriot, S | 1 |
| Auvin, S | 1 |
| Vallée, L | 1 |
| Fulton, JA | 1 |
| Kahn, J | 1 |
| Nelson, LS | 1 |
| Hoffman, RS | 1 |
| Gershovich, OE | 1 |
| Billups, SJ | 1 |
| Delate, T | 1 |
| Hoffman, CK | 1 |
| Carroll, N | 1 |
| Mauskop, A | 3 |
| Iversen, HK | 1 |
| Filho, PF | 1 |
| Bell, CF | 1 |
| Foley, KA | 1 |
| Barlas, S | 1 |
| Solomon, G | 2 |
| Ahonen, K | 1 |
| Hämäläinen, ML | 1 |
| Eerola, M | 1 |
| Sunshine, A | 1 |
| Mulhern, SA | 1 |
| Olson, N | 1 |
| Elkind, A | 1 |
| Almas, M | 1 |
| Sikes, C | 1 |
| Olesen, J | 1 |
| Curro, G | 1 |
| Baccarani, U | 1 |
| Adani, GL | 1 |
| Lorenzin, D | 1 |
| Bresadola, F | 1 |
| Acuto, G | 1 |
| Caiola, F | 1 |
| Díez, FI | 1 |
| Straube, A | 1 |
| Mannix, LK | 5 |
| Loder, E | 3 |
| Mueller, L | 2 |
| Chen, Y | 1 |
| Ma, L | 1 |
| Vieira, DS | 1 |
| Naffah-Mazzacoratti, Mda G | 1 |
| Zukerman, E | 1 |
| Senne Soares, CA | 1 |
| Cavalheiro, EA | 1 |
| Peres, MF | 1 |
| Hustad, C | 1 |
| Ramsey, K | 1 |
| Silver, S | 1 |
| Gano, D | 1 |
| Gerretsen, P | 1 |
| Facco, E | 1 |
| Liguori, A | 1 |
| Petti, F | 1 |
| Zanette, G | 1 |
| Coluzzi, F | 1 |
| De Nardin, M | 1 |
| Mattia, C | 1 |
| Seidman, LS | 1 |
| Hamid, MA | 1 |
| Jensen, RH | 1 |
| Pringsheim, T | 1 |
| Davenport, WJ | 1 |
| Dodick, D | 1 |
| Claghorn, J | 1 |
| Sramek, JJ | 1 |
| Block, G | 3 |
| Panebianco, D | 1 |
| Cheng, H | 3 |
| Olah, TV | 2 |
| Terwindt, GM | 1 |
| Jiang, K | 5 |
| Sciberras, DG | 1 |
| Polvino, WJ | 1 |
| Gertz, BJ | 1 |
| Stepanavage, M | 2 |
| Wittreich, J | 1 |
| Olah, T | 1 |
| Edwards, M | 1 |
| Mant, T | 1 |
| Cumberbatch, MJ | 1 |
| Hill, RG | 3 |
| Williamson, DJ | 2 |
| Shepheard, SL | 2 |
| Gijsman, H | 1 |
| Sargent, J | 1 |
| Tuchman, M | 2 |
| Teall, J | 2 |
| Polis, AB | 1 |
| Hartmaier, SL | 1 |
| Block, GA | 3 |
| Cutler, N | 1 |
| Gross, M | 1 |
| Willoughby, E | 2 |
| Smith, B | 1 |
| Reines, S | 1 |
| Steiner, TJ | 1 |
| MaassenVanDenBrink, A | 1 |
| Reekers, M | 1 |
| Bax, WA | 1 |
| Saxena, PR | 1 |
| Getson, A | 2 |
| Amaraneni, PG | 1 |
| Solbach, MP | 1 |
| McHugh, W | 1 |
| Feighner, J | 1 |
| Silberstein, S | 2 |
| Lee, Y | 1 |
| Ermlich, SJ | 1 |
| Sterrett, AT | 1 |
| Blum, RA | 1 |
| McLoughlin, DA | 1 |
| Zhao, J | 1 |
| Rogers, JD | 2 |
| Davies, GM | 2 |
| Lerner, D | 1 |
| Ahrens, SP | 1 |
| Farmer, MV | 1 |
| Williams, DL | 1 |
| Deleu, D | 2 |
| Hanssens, Y | 2 |
| Bomhof, M | 1 |
| Paz, J | 1 |
| Legg, N | 1 |
| Vandormael, K | 5 |
| Patel, K | 3 |
| Dooley, M | 1 |
| Faulds, D | 1 |
| Vyas, KP | 1 |
| Halpin, RA | 1 |
| Geer, LA | 1 |
| Ellis, JD | 1 |
| Liu, L | 1 |
| Chavez-Eng, C | 1 |
| Matuszewski, BK | 1 |
| Varga, SL | 1 |
| Guiblin, AR | 1 |
| Vishwanathan, K | 1 |
| Bartlett, MG | 1 |
| Stewart, JT | 1 |
| Logemann, CD | 1 |
| Rankin, LM | 1 |
| Leira, R | 1 |
| Von Seggern, RL | 1 |
| Mathew, NT | 1 |
| Kailasam, J | 1 |
| Gentry, P | 1 |
| Chernyshev, O | 1 |
| Dahlof, CG | 2 |
| Le Jeunne, C | 1 |
| Bartleson, JD | 1 |
| Vega, P | 1 |
| de Hoon, JN | 1 |
| Willigers, JM | 1 |
| Troost, J | 1 |
| Struijker-Boudier, HA | 1 |
| Van Bortel, LM | 1 |
| Scholz, M | 1 |
| Lipton, RB | 6 |
| Saper, JR | 2 |
| Ryan, RE | 1 |
| Solomon, GD | 1 |
| Potrebic, S | 1 |
| Raskin, NH | 2 |
| Dasbach, EJ | 1 |
| Carides, GW | 1 |
| Pigeon, JG | 1 |
| Wiebe, S | 1 |
| Heinze, A | 1 |
| Heinze-Kuhn, K | 1 |
| Lindner, V | 1 |
| Hernandez, JF | 1 |
| Hashimoto, S | 1 |
| Iwata, M | 1 |
| Malbecq, W | 1 |
| Solomon, S | 1 |
| Frishberg, B | 1 |
| Markson, L | 1 |
| Berger, M | 1 |
| Crawford, G | 1 |
| Ahrens, S | 2 |
| Hairwassers, D | 1 |
| Brandes, JL | 1 |
| Bohidar, N | 1 |
| Wang, L | 1 |
| Boyle, D | 1 |
| Guerra, F | 1 |
| Oldman, AD | 1 |
| Smith, LA | 1 |
| McQuay, HJ | 1 |
| Zhang, Q | 1 |
| Newman, LC | 1 |
| Roon, KI | 1 |
| Freitag, FG | 1 |
| Cowan, R | 1 |
| Markson, LE | 1 |
| Berger, ML | 1 |
| Evans, JK | 1 |
| Fité, B | 1 |
| Plosker, GL | 1 |
| Barbosa, JS | 1 |
| Seidelin, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mind-body Treatments for Chronic Back Pain[NCT03294148] | 151 participants (Actual) | Interventional | 2017-08-07 | Completed | |||
| Effect of Information on Placebo in the Informed Consent on the Trial Outcomes and Participant Blinding[NCT04182295] | 89 participants (Actual) | Interventional | 2019-10-07 | Completed | |||
| Open-Label Placebo Treatment of Women With Premenstrual Syndrome: A Randomized Controlled Trial[NCT03547661] | 150 participants (Actual) | Interventional | 2018-08-02 | Completed | |||
| The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache[NCT00719134] | Phase 4 | 76 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors[NCT02522988] | 74 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine[NCT00897104] | Phase 3 | 933 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| A Randomized, Triple-Blind, Placebo-Controlled, Outpatient Study to Examine the Safety and Efficacy of MK462 10 mg p.o. in the Treatment of Multiple Attacks of Migraine Headache[NCT00899379] | Phase 3 | 473 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence[NCT00897949] | Phase 3 | 1,473 participants (Actual) | Interventional | 1995-03-31 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild[NCT00095004] | Phase 3 | 167 participants (Actual) | Interventional | 2004-10-21 | Completed | ||
| A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine[NCT00898677] | Phase 3 | 1,268 participants (Actual) | Interventional | 1995-09-30 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild[NCT00092963] | Phase 3 | 529 participants (Actual) | Interventional | 2004-08-17 | Completed | ||
| TreximetTM in the Prevention and Modification of Disease Progression in Migraine[NCT01300546] | Phase 4 | 40 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine[NCT00516737] | Phase 3 | 207 participants (Actual) | Interventional | 2007-10-03 | Completed | ||
| Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine[NCT00772473] | 34 participants (Actual) | Observational | 2008-02-29 | Completed | |||
| Calcitonin Gene-related Peptide (CGRP) Levels in the Pathogenesis of Chronic Migraine[NCT01071096] | Phase 4 | 20 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| The Effect of Daylight Saving Time Transitions on Sleep and Migraine Headaches.[NCT05742191] | 50 participants (Anticipated) | Observational | 2023-02-06 | Recruiting | |||
| Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs[NCT00360282] | 36 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura[NCT00443209] | Phase 3 | 1,068 participants (Actual) | Interventional | 2007-02-21 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders[NCT00894556] | Phase 3 | 109 participants (Actual) | Interventional | 2009-06-10 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis[NCT00812006] | Phase 3 | 108 participants (Actual) | Interventional | 2009-03-24 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years[NCT00604812] | Phase 1 | 31 participants (Actual) | Interventional | 2007-12-17 | Completed | ||
| A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms.[NCT00753311] | Phase 4 | 80 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents[NCT01001234] | Phase 3 | 1,382 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura[NCT01004263] | Phase 3 | 674 participants (Actual) | Interventional | 2009-12-01 | Completed | ||
| A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura[NCT00877838] | Phase 2 | 40 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine[NCT00111722] | Phase 3 | 393 participants (Actual) | Interventional | 2005-05-27 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine[NCT00111709] | Phase 3 | 393 participants (Actual) | Interventional | 2005-05-27 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated With Rizatriptan Orally Disintegrating Tablet (ODT)[NCT00250458] | Phase 3 | 346 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Effects of Myofascial Trigger Points Therapy in Migraine.[NCT05646160] | 100 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1-week average pain intensity, 0 - 10 numerical rating scale, where a higher score indicates more pain. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 1.18 |
| Placebo | 2.84 |
| Usual Care | 3.13 |
Questionnaire to rate negative affect, scores range from 5 - 25, with a higher score meaning a stronger negative affect (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 8.30 |
| Placebo | 7.70 |
| Usual Care | 8.19 |
Back pain disability questionnaire measured on a scale of 0-100. A higher score indicates a higher severity of disability. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 10.14 |
| Placebo | 19.00 |
| Usual Care | 20.68 |
Questionnaire used to help quantify an individual's pain experience. Measured 0-52. A higher score means a higher level of catastrophizing. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 8.30 |
| Placebo | 7.70 |
| Usual Care | 8.19 |
Post-treatment-only outcome measure depicting a patient's subjective rating of overall improvement. Score ranges from 1-7 with a higher score indicating a higher level of change and improvement (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 6.14 |
| Placebo | 3.61 |
| Usual Care | 2.06 |
Questionnaire to rate positive affect, scores range from 5 - 25, a higher score means stronger affect (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 17.89 |
| Placebo | 15.20 |
| Usual Care | 14.98 |
Questionnaire measuring anger (5 items) with a score range of 5-25. Higher scores indicate a higher severity of anger. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 9.52 |
| Placebo | 9.89 |
| Usual Care | 10.45 |
Questionnaire measuring anxiety (8 items). Scores range from 8-40 with a higher score meaning more severe levels of fear, anxious misery, hyperarousal, and somatic symptoms related to arousal. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 15.02 |
| Placebo | 13.89 |
| Usual Care | 14.11 |
Questionnaire measuring sleep disturbance (8 items). Scores range from 8-40. Higher scores indicate higher levels of sleep disturbance (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 17.73 |
| Placebo | 20.50 |
| Usual Care | 20.89 |
Questionnaire measuring depression (8 items). Scores range from 8-32. A higher score indicates higher levels of depressive symptoms (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 12.23 |
| Placebo | 11.75 |
| Usual Care | 11.81 |
Questionnaire used to assess the subjective rating of kinesiophobia or fear of movement. Scores range from 11-44 with higher scores indicating greater fear of pain, movement, and injury. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 16.41 |
| Placebo | 22.16 |
| Usual Care | 22.51 |
Questionnaire used to assess daily drinking (number of drinks consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Drinks (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 11.63 |
| Placebo | 12.88 |
| Usual Care | 8.02 |
Questionnaire used to assess daily cannabis use (number of grams consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Grams of cannabis (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 6.76 |
| Placebo | 3.31 |
| Usual Care | 1.49 |
Questionnaire used to assess daily opioid use (number of pills consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Opioid pills (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 1.29 |
| Placebo | 0.36 |
| Usual Care | 1.77 |
Post-treatment-only outcome measure depicting the patient's satisfaction with the treatment. Measured 0 - 100. A higher score means higher satisfaction with treatment/ (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 92.40 |
| Placebo | 57.61 |
| Usual Care | 36.86 |
The primary outcome measure was the change in headache between the baseline pain score recorded 30 min after the onset of headache and the pain score recorded 2 hours later as measured on a visual analog scale ranging from 0 (no pain) to 10 (worst pain imaginable). (NCT00719134)
Timeframe: 2 hours after treatment
| Intervention | percent change (Mean) | |
|---|---|---|
| percent change with Maxalt | percent change with placebo | |
| All Participants | -47.6 | -20.7 |
A secondary measure of attack outcome was based on categorical classification of the pain freedom (pain score = 0) 2.5 hours after onset of headache. (NCT00719134)
Timeframe: 2 hours after treatment
| Intervention | percent of patients pain free (Number) | |
|---|---|---|
| pain free with maxalt | pain free with placebo | |
| All Participants | 25.5 | 6.6 |
Duration of relief or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1) was calculated for responders who had a headache recurrence (NCT00897104)
Timeframe: 24 hours
| Intervention | Hours (Mean) |
|---|---|
| Rizatriptan 5 mg | 11.07 |
| Sumatriptan 5 mg | 11.58 |
| Placebo | 14.38 |
Participants with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each participant rated functional disability on a 4-grade scale (0 =normal; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 =unable to carry out daily activities, required bed rest). (NCT00897104)
Timeframe: 2 hours after treatment
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Normal | Mildly Impaired | Severely Impaired | Required Bed Rest | |
| Placebo | 4 | 28 | 18 | 30 |
| Rizatriptan 5 mg | 108 | 152 | 38 | 52 |
| Sumatriptan 5 mg | 116 | 148 | 42 | 49 |
Participants pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each participant rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain). (NCT00897104)
Timeframe: 2 hours after treatment
| Intervention | Participants (Number) | |
|---|---|---|
| 2-hour pain freedom | No 2-hour pain freedom | |
| Placebo | 2 | 78 |
| Rizatriptan 5 mg | 95 | 257 |
| Sumatriptan 5 mg | 113 | 243 |
Participants reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment (NCT00897104)
Timeframe: 2 hours after treatment
| Intervention | Participants (Number) | |
|---|---|---|
| 2-hour pain relief | No 2-hour pain relief | |
| Placebo | 18 | 62 |
| Rizatriptan 5 mg | 223 | 129 |
| Sumatriptan 5 mg | 238 | 118 |
Escape medication is defined as rescue medication for participants who experienced lack of efficacy from the study medication. (NCT00897104)
Timeframe: 2 hours after treatment
| Intervention | Participants (Number) | |
|---|---|---|
| Used Escape Medication | Did not Use Escape Medication | |
| Placebo | 33 | 47 |
| Rizatriptan 5 mg | 73 | 282 |
| Sumatriptan 5 mg | 55 | 302 |
Participants who recorded the presence or absence of the associated symptoms photophobia, phonophobia, nausea, and vomiting at 2 hours after treatment. (NCT00897104)
Timeframe: 2 hours after treatment
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2-hour Photophobia | No 2-hour Photophobia | 2-hour Phonophobia | No 2-hour Phonophobia | 2-hour Nausea | No 2-hour Nausea | Not Analyzed for Nausea | 2-hour Vomiting | No 2-hour Vomiting | Not Analyzed for Vomiting | |
| Placebo | 66 | 14 | 47 | 33 | 48 | 30 | 2 | 6 | 67 | 7 |
| Rizatriptan 5 mg | 161 | 189 | 126 | 224 | 105 | 243 | 2 | 12 | 330 | 8 |
| Sumatriptan 5 mg | 153 | 201 | 125 | 229 | 131 | 221 | 2 | 12 | 330 | 12 |
Participants reporting time to relief (defined as the first time that a participant reported grade 0 or 1 in headache severity within 2 hours after treatment (for the comparison of rizatriptan 5 mg and sumatriptan 50 mg). (NCT00897104)
Timeframe: within 2 hours after treatment
| Intervention | Participants (Number) | |
|---|---|---|
| First pain relief within 2 hrs | Pain relief did not occur within 2 hrs | |
| Placebo | 24 | 56 |
| Rizatriptan 5 mg | 231 | 121 |
| Sumatriptan 5 mg | 247 | 109 |
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) at baseline to grades 0 or 1 (no headache or mild) at 2 hours after initial dosing for the first migraine attack (NCT00899379)
Timeframe: 2 hours
| Intervention | participants (Number) | |
|---|---|---|
| Reporting pain relief | Not reporting pain relief | |
| Placebo | 30 | 52 |
| Rizatriptan 10 mg | 246 | 74 |
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the fourth migraine attack (NCT00899379)
Timeframe: 2 hours
| Intervention | Participants (Number) | |
|---|---|---|
| Reporting pain relief | Not reporting pain relief | |
| Placebo | 31 | 26 |
| Rizatriptan 10 mg | 190 | 65 |
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the second migraine attack (NCT00899379)
Timeframe: 2 hours
| Intervention | Participants (Number) | |
|---|---|---|
| Reporting pain relief | Not reporting pain relief | |
| Placebo | 27 | 46 |
| Rizatriptan 10 mg | 228 | 63 |
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the third migraine attack (NCT00899379)
Timeframe: 2 hours
| Intervention | Participants (Number) | |
|---|---|---|
| Reporting pain relief | Not reporting pain relief | |
| Placebo | 21 | 54 |
| Rizatriptan 10 mg | 207 | 52 |
Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 - Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest (NCT00897949)
Timeframe: 2 hours after initial dose of test drug
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Normal | Mildly Impaired | Severely Impaired | Requires Bedrest | |
| Placebo | 54 | 118 | 53 | 75 |
| Rizatriptan 10 mg | 209 | 148 | 45 | 52 |
| Rizatriptan 5 mg | 175 | 160 | 56 | 66 |
Patients reporting pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug
| Intervention | Participants (Number) | |
|---|---|---|
| Reporting no pain | Reporting pain | |
| Placebo | 30 | 272 |
| Rizatriptan 10 mg | 193 | 262 |
| Rizatriptan 5 mg | 150 | 307 |
Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours). (NCT00897949)
Timeframe: 2 hours after treatment for recurrence
| Intervention | Participants (Number) | |
|---|---|---|
| Pain relief | No pain relief | |
| Placebo / Rizatriptan 10 mg | 18 | 4 |
| Placebo / Rizatriptan 5 mg | 12 | 5 |
| Rizatriptan 10 mg / Placebo | 33 | 42 |
| Rizatriptan 10 mg / Rizatriptan 10 mg | 53 | 12 |
| Rizatriptan 5 mg / Placebo | 32 | 27 |
| Rizatriptan 5 mg / Rizatriptan 5 mg | 39 | 16 |
Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug
| Intervention | Participants (Number) | |
|---|---|---|
| Reporting pain relief | Not reporting pain relief | |
| Placebo | 106 | 196 |
| Rizatriptan 10 mg | 322 | 133 |
| Rizatriptan 5 mg | 285 | 172 |
(NCT00897949)
Timeframe: 2 hours after initial dose of test drug
| Intervention | Participants (Number) | |
|---|---|---|
| Used escape medication | Did not use escape medication | |
| Placebo | 128 | 176 |
| Rizatriptan 10 mg | 76 | 380 |
| Rizatriptan 5 mg | 101 | 357 |
Patients with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each patient rated functional disability on a 4-grade scale (0 = no functional disability; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 = unable to carry out daily activities, requires bed rest). (NCT00898677)
Timeframe: 2 hours after dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| No functional disability | Mildly impaired | Severely impaired | Required bed rest | |
| Placebo | 31 | 59 | 33 | 36 |
| Rizatriptan 10 mg | 160 | 123 | 60 | 42 |
| Rizatriptan 5 mg | 52 | 62 | 27 | 23 |
| Sumatriptan 100 mg | 126 | 142 | 67 | 52 |
Patients who recorded the presence or absence of nausea 2 hours after dose (NCT00898677)
Timeframe: 2 hours after dose
| Intervention | participants (Number) | |
|---|---|---|
| 2-hour Nausea | No 2-hour Nausea | |
| Placebo | 68 | 91 |
| Rizatriptan 10 mg | 95 | 290 |
| Rizatriptan 5 mg | 37 | 127 |
| Sumatriptan 100 mg | 128 | 259 |
Patients pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each patient rated headache severity on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain). (NCT00898677)
Timeframe: 2 hours after dose
| Intervention | Participants (Number) | |
|---|---|---|
| 2-hour Pain freedom | No 2-hour pain freedom | |
| Placebo | 15 | 139 |
| Rizatriptan 10 mg | 155 | 230 |
| Rizatriptan 5 mg | 41 | 123 |
| Sumatriptan 100 mg | 127 | 260 |
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment (NCT00898677)
Timeframe: 2 hours after dose
| Intervention | Participants (Number) | |
|---|---|---|
| 2-hour pain relief | No 2-hour pain relief | |
| Placebo | 64 | 95 |
| Rizatriptan 10 mg | 258 | 127 |
| Rizatriptan 5 mg | 99 | 65 |
| Sumatriptan 100 mg | 239 | 148 |
Patients reporting time to relief defined as the first time point at which a patient reported headache severity grade 1 or 0 (mild pain or no headache) within 2 hours after dose (NCT00898677)
Timeframe: within 2 hours after dose
| Intervention | Participants (Number) | |
|---|---|---|
| First pain relief within 2 hrs | Pain relief did not occur within 2 hrs | |
| Placebo | 72 | 87 |
| Rizatriptan 10 mg | 265 | 120 |
| Rizatriptan 5 mg | 102 | 62 |
| Sumatriptan 100 mg | 247 | 140 |
Self-assessed grade of compliance with lifestyle modification changes (where A=1, B=2, C=3, D=4, and F=5; lower scores represent better outcomes) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Day 121
| Intervention | scores on a scale (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | 2.33 |
| Naproxen Sodium | 2.43 |
Comparing the number of migraine headache days during Baseline Period Days 1-30 to number or migraine headache days reported in Treatment Period Days 91-120 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change=[ (total headache days during Treatment Period Month 3 (Days 91-120)-total headache days during Baseline (Days 1-30)/total headache days during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Day 121 (following 30 day Baseline Period and Treatment Period Days 91-120)
| Intervention | percent change of headache days (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | -13.50 |
| Naproxen Sodium | -36.50 |
Total number of doses of study medication reported taken per participant in Treatment Period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | doses of study medication (Mean) | ||
|---|---|---|---|
| Treatment Period Month 1 | Treatment Period Month 2 | Treatment Period Month 3 | |
| Naproxen Sodium | 9.36 | 8.86 | 8.50 |
| Sumatriptan/Naproxen Sodium | 11.00 | 10.28 | 10.28 |
Number of subjects with at least a 50% reduction in number of headache days reported in Baseline versus Treatment period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 3 | 3 | 6 |
| Sumatriptan/Naproxen Sodium | 1 | 2 | 3 |
Comparing the number of migraine attacks reported from Baseline to the number of migraine attacks reported in Treatment Period Months 1(Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Each treatment month percent change was individually compared to Baseline. The following formula was used for each treatment period calculation. e.g.,Percent change=[ (total migraine attacks days during Treatment Period Month 3 (Days 91-120)-total migraine attacks during Baseline (Days 1-30)/total migraine attacks during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine attacks (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -12.23 | -9.03 | -39.12 |
| Sumatriptan/Naproxen Sodium | -4.35 | -2.88 | -8.63 |
Number of subjects with at least a 50% reduction in number of migraine attacks reported in Baseline versus Treatment period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 1 | 0 | 6 |
| Sumatriptan/Naproxen Sodium | 3 | 2 | 4 |
"Change in MIDAS total score from end of Baseline (Day 31) to end Treatment Period month 3 (Day 121) in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Total score of disability ranges:~0 to 5, MIDAS Grade I, Little or no disability~6 to 10, MIDAS Grade II, Mild disability~11 to 20, MIDAS Grade III, Moderate disability~21+, MIDAS Grade IV, Severe disability No subscales are present." (NCT01300546)
Timeframe: Baseline MIDAS collected at Day 31, Post final dose study medication MIDAS collected at Day 121.
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline Day 31 | Day 121 | |
| Naproxen Sodium | 22.6 | 24.1 |
| Sumatriptan/Naproxen Sodium | 28.7 | 27.9 |
Comparing mean migraine duration from onset to painfree from Baseline(Days 1-30) to each month: Treatment Period Months 1 (Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from Treatment Period Month 3 and Baseline, then comparing the average change between each arm. The following formula was used for each treatment period calculation. e.g.,Percent change=[(mean duration from onset to painfree during Treatment Period Month 3 (Days 91-120)- mean duration from onset to painfree during Baseline (Days 1-30)/mean duration from onset to painfree during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -14.92 | -26.35 | 70.84 |
| Sumatriptan/Naproxen Sodium | 72.04 | 35.86 | 61.96 |
"% change from Baseline in mean migraine duration from time of treatment to pain free reported in Treatment Period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Percent change=[(mean duration from treatment to painfree during Treatment Period Month 3 (Days 91-120)- mean duration from treatment to painfree during Baseline (Days 1-30)/mean duration from treatment to painfree during Baseline (Days 1-30)]*100%)." (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -14.91 | -25.52 | 73.42 |
| Sumatriptan/Naproxen Sodium | 150.10 | 92.73 | 114.10 |
Comparing migraine severity 2 hours after treatment from Baseline(Days 1-30) to migraine severity reported 2 hours after treatment in Treatment Period Months 1 (Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from Treatment Period Month 3 and Baseline, then comparing the average change between each arm. The following formula was used for each treatment period calculation. e.g.,Percent change=[ (mean migraine severity during Treatment Period Month 3 (Days 91-120)- mean migraine severity during Baseline (Days 1-30)/mean migraine severity during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine severity (Mean) | ||
|---|---|---|---|
| 2 hours after treatment for Baseline to Month 1 | 2 hours after treatment for Baseline to Month 2 | 2 hours after treatment for Baseline to Month 3 | |
| Naproxen Sodium | 11.78 | 0.33 | 32.62 |
| Sumatriptan/Naproxen Sodium | -17.84 | -36.71 | -55.60 |
Comparing the number of migraine headache days during Baseline Period Days 1-30 to number or migraine headache days reported in Treatment Period Month 1 (Days 31-60), Treatment Period Month 2 (Days 61-90), and Treatment Period Month 3 (Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. e.g., Percent change=[ (total headache days during Treatment Period Month 3 (Days 91-120)-total headache days during Baseline (Days 1-30)/total headache days during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine headache days (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -26.86 | -21.44 | -36.50 |
| Sumatriptan/Naproxen Sodium | -1.70 | -4.39 | -13.50 |
% change in number of doses during Baseline of triptans (Group A) and non-steroidal anti-inflammatory drugs(NSAIDs) (Group B) vs. doses during Treatment Period Months 1, 2, and 3 of study medication in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. e.g.,Percent change=[(number of doses during Treatment Period Month 3 (Days 91-120)- number of doses during Baseline (Days 1-30)/number of doses during Baseline (Days 1-30)]*100%). The total number of subjects used in this analysis is different than the total number of subjects as the analysis is only looking at those subjects that were taking one of the study medications during Baseline. (NCT01300546)
Timeframe: Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of study medication (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 160.8 | 76.4 | 112.7 |
| Sumatriptan/Naproxen Sodium | 130.8 | 114.9 | 96.1 |
Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild), 2 (moderate), or 3 (severe). Pain free = rating of 0 (no pain) at 2 hours post-dose. (NCT00516737)
Timeframe: 2 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Rizatriptan 10 mg ODT | 61 |
| Placebo | 27 |
24-hour sustained pain freedom (defined as pain freedom from 2 to 24 hours post-dose and no use of rescue medication). Participants assessed pain severity and use of rescue medication on a paper diary. (NCT00516737)
Timeframe: 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Rizatriptan 10 mg ODT | 48 |
| Placebo | 17 |
"Level of functional disability was assessed on a paper diary by the participants.~Level of functional disability was rated as: normal, mildly impaired, severely impaired or unable to do activities, requires bed rest. Absence of functional disability defined as a rating of normal at 2 hours post-dose." (NCT00516737)
Timeframe: 2 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Rizatriptan 10 mg ODT | 66 |
| Placebo | 42 |
Absence or presence of nausea was recorded by the participants on a paper diary. Absence is defined as no nausea at 2 hours post-dose. (NCT00516737)
Timeframe: 2 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Rizatriptan 10 mg ODT | 82 |
| Placebo | 73 |
Absence or presence of phonophobia was recorded by the participants on a paper diary. Absence is defined as no phonophobia at 2 hours post-dose. (NCT00516737)
Timeframe: 2 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Rizatriptan 10 mg ODT | 72 |
| Placebo | 55 |
Absence or presence of photophobia was recorded by the participants on a paper diary. Absence is defined as no photophobia at 2 hours post-dose. (NCT00516737)
Timeframe: 2 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Rizatriptan 10 mg ODT | 69 |
| Placebo | 43 |
Participants recorded use of any rescue medication up to 24 hours after dosing with study medication on a paper diary. (NCT00516737)
Timeframe: 24 hours post-dose
| Intervention | Participants (Number) |
|---|---|
| Rizatriptan 10 mg ODT | 61 |
| Placebo | 32 |
Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary. (NCT01071096)
Timeframe: Baseline (collected historically at screening) versus (vs.) Month (Mo) 1, Mo 2, Mo 3, Mo 4, Mo 5, Mo 6, and Mo 7
| Intervention | days (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline vs. Month 1 | Baseline vs. Month 2 | Baseline vs. Month 3 | Baseline vs. Month 4 | Baseline vs. Month 5 | Baseline vs. Month 6 | Baseline vs. Month 7 | |
| Group A | -7.61 | -9.72 | -10.06 | -9.50 | -8.94 | -9.50 | -6.50 |
| Group B | -6.67 | -5.22 | -5.22 | -6.89 | -6.33 | -9.22 | -4.56 |
Baseline number of headache days per month collected historically at screening. Post-treatment number of headache days collected per month via diary. (NCT01071096)
Timeframe: Baseline (collected historically at screening) vs. Mo 1, Mo 1 vs. Mo 2, Mo 2 vs. Mo 3, Mo 3 vs. Mo 4, Mo 4 vs. Mo 5, Mo 5 vs. Mo 6, and Mo 6 vs. Mo 7
| Intervention | days (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline vs. Mo 1 | Mo 1 vs. Mo 2 | Mo 2 vs. Mo 3 | Mo 3 vs. Mo 4 | Mo 4 vs. Mo 5 | Mo 5 vs. Mo 6 | Mo 6 vs. M 7 | |
| Group A | -7.61 | -2.11 | -0.33 | 0.56 | 0.56 | -0.56 | 3.00 |
| Group B | -6.67 | 1.44 | 0.00 | -1.67 | 0.56 | -2.89 | 4.67 |
Only cytokines with a mean densimetric value 1.65 times the background grey value in a minimum of 3 patients were considered detectable. These are reported below. Values normalized to positive control array spots after background subtraction: C5/C5a, CD40 Ligand, Granulocyte Colony Stimulating Factor (G-CSF), Growth Regulated Oncogene(GRO)-alpha, Soluble Intercellular Adhesion Molecule (sICAM)-1, Interferon gamma (IFN-y), Interleukin(IL)-1alpha, 1beta, 1ra, 8, 16, 17E, & 23, Interferon Gamma-Induced Protein 10 (IP-10), Interferon-inducible T cell alpha chemoattractant (I-TAC), Macrophage Migration Inhibitory Factor (MIF), Serpin E1, and Regulated Upon Activation Normal T-cell Expressed (RANTES) (NCT01071096)
Timeframe: For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3 at Baseline level (inter-ictal) and at onset of headache that is one degree worse than Baseline level and that will be treated with acute therapy
| Intervention | Florescent Units (FU) (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C5/C5a | CD40 Ligand | G-CSF | GROa | sICAM-1 | IFN-y | IL-1alpha | IL-1beta | IL-1ra | IL-8 | IL-16 | IL-17E | IL-23 | IP-10 | I-TAC | MIF | Serpin E1 | RANTES | |
| Month 1 vs. Month 3 Non-Responders | 3.26 | 1.22 | 1.34 | 0.73 | 1.51 | 1.63 | 0.81 | 1.03 | 1.30 | 2.28 | 1.10 | 1.45 | 2.61 | 3.11 | 3.65 | 1.24 | 3.16 | 1.24 |
| Month 1 vs. Month 3 Responders | 1.03 | 0.91 | 1.07 | 1.05 | 3.99 | 0.91 | 0.86 | 1.15 | 0.88 | 4.38 | 0.98 | 1.28 | 0.93 | 1.55 | 0.67 | 0.80 | 0.76 | 1.14 |
| Month 1 vs. Saline Non-Responders | 1.01 | 1.26 | 0.93 | 3.18 | 0.61 | 0.80 | 2.88 | 1.12 | 2.02 | 1.70 | 2.07 | 1.02 | 1.80 | 0.95 | 0.28 | 9.55 | 0.70 | 0.77 |
| Month 1 vs. Saline Responders | 1.38 | 1.09 | 0.92 | 1.34 | 2.60 | 1.29 | 2.30 | 1.63 | 1.13 | 1.61 | 0.91 | 0.86 | 2.45 | 1.32 | 1.40 | 3.71 | 0.98 | 0.95 |
| Month 3 vs. Saline Non-Responders | 1.61 | 1.31 | 0.99 | 1.81 | 2.00 | 1.92 | 2.14 | 0.51 | 1.90 | 1.22 | 1.97 | 0.42 | 1.69 | 2.76 | 0.94 | 8.66 | 0.90 | 0.91 |
| Month 3 vs. Saline Responders | 1.39 | 0.98 | 0.85 | 1.40 | 5.99 | 1.29 | 1.50 | 1.38 | 0.96 | 2.71 | 0.75 | 1.59 | 1.06 | 0.86 | 1.01 | 2.71 | 0.70 | 0.93 |
CGRP Level collected each month when subject did not have a headache or was at lowest pain level of headache that month. (NCT01071096)
Timeframe: Baseline levels collected for OnabotulinumtoxinA and Saline treatment during Months 1 through 7
| Intervention | pmol/mg total protein (Mean) | ||
|---|---|---|---|
| Treatment Month 1 | Treatment Month 2 | Treatment Month 3 | |
| OnabotulinumtoxinA | 39.64 | 28.37 | 26.14 |
| Saline | 40.79 | 39.14 | 50.63 |
Saliva samples collected at Baseline (at no headache or lowest level of headache), at headache attack directly before taking rescue medication and 2 hours after treating with rescue medication. (NCT01071096)
Timeframe: For OnabotulinumtoxinA and Saline treatment months 1, 2 and 3
| Intervention | pmol/mg total protein (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment Month 1 - Baseline | Treatment Month 1 - Attack | Treatment Month 1 - 2 Hours Post | Treatment Month 2 - Baseline | Treatment Month 2 - Attack | Treatment Month 2 - 2 Hours Post | Treatment Month 3 - Baseline | Treatment Month 3 - Attack | Treatment Month 3 - 2 Hours Post | |
| OnabotulinumtoxinA Non-Responders | 29.36 | 22.36 | 23.66 | 28.66 | 32.65 | 22.35 | 32.61 | 30.17 | 19.11 |
| OnabotulinumtoxinA Responders | 52.36 | 27.94 | 61.55 | 59.89 | 60.14 | 39.13 | 51.33 | 73.18 | 54.04 |
| Saline | 70.46 | 36.23 | 39.76 | 44.12 | 33.05 | 33.93 | 58.74 | 46.16 | 49.39 |
Scores are based on a scale developed by Graybiel which rates seven subjective and objective signs of motion sickness. The total scores ranged from from 0 to 25. Zero indicating no motion sickness. Greater than 16 indicates severe motion sickness. Trials were stopped if scores were 16 or greater. Scores were taken before and after each rotation. (NCT00360282)
Timeframe: Pre and Post Stimulus (about 6 minutes apart)
| Intervention | units on a scale (Median) |
|---|---|
| Rizatriptan Visit | 5.1 |
| Placebo Visit | 9 |
Subjective report of distress ranging from 0 to 10 based on the method of Wolpe. Zero indicates no distress and 10 indicates severe distress. Measures used in this analysis match the times used in the analysis for Outcome 1. (NCT00360282)
Timeframe: Pre and Post Stimulus (6 minutes apart)
| Intervention | units on a scale (Median) |
|---|---|
| Rizatriptan Visit | 3 |
| Placebo Visit | 2 |
Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PF at 2 hours post-dose is defined as a decrease from mild, moderate or severe migraine headache (Grade 1, 2, or 3) at baseline to no pain (Grade 0) 2 hours post-dose. (NCT00443209)
Timeframe: 2 hours post-dose (Up to 18 months)
| Intervention | Percentage of Migraine Attacks (Mean) |
|---|---|
| Telcagepant 280 mg/300 mg | 38.9 |
| Rizatriptan 10 mg | 47.5 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination. Participants were monitored for clinical AEs for 14 days after any dose of study drug. (NCT00443209)
Timeframe: Within 14 days of any dose of study drug (Up to 18.5 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Telcagepant 280 mg/300 mg | 58.7 |
| Rizatriptan 10 mg | 63.9 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants were monitored for laboratory AEs for 14 days after any dose of study drug. (NCT00443209)
Timeframe: Within 14 days of any dose of study drug (Up to 18.5 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Telcagepant 280 mg/300 mg | 1.9 |
| Rizatriptan 10 mg | 1.6 |
Triptan-related AEs are defined as: chest pain, chest tightness, asthenia, paraesthesia, dysaesthesia or hyperaesthesia. Participants were monitored for triptan-related AEs for 14 days after any dose of study drug. (NCT00443209)
Timeframe: Within 14 days of any dose of study drug (Up to 18.5 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Telcagepant 280 mg/300 mg | 5.0 |
| Rizatriptan 10 mg | 11.2 |
Predefined limits of change were established for vital sign measurements: Systolic Blood Pressure (>=180 mm Hg and 20 mm Hg increase OR <=90 mm Hg and 20 mm Hg decrease), Diastolic Blood Pressure (>=105 mm Hg and 15 mm Hg increase OR <=50 mm Hg and 15 mm Hg decrease), Pulse (>=120 beats per minute [bpm] and 15 bpm increase OR <=50 bpm and 15 bpm decrease), Body Temperature (>38º C [oral equivalent]) and Respiratory Rate (>25 or increase of 10 OR <5 or decrease of 10 [per minute]). Participants were monitored for vital sign measurements outside predefined limits of change for 14 days after any dose of study drug. (NCT00443209)
Timeframe: Within 14 days of any dose of study drug (Up to 18.5 months)
| Intervention | Percentage of Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Systolic Blood Pressure Increase | Systolic Blood Pressure Decrease | Diastolic Blood Pressure Increase | Diastolic Blood Pressure Decrease | Pulse Increase | Pulse Decrease | Body Temperature Increase | Respiratory Rate Increase or Decrease | |
| Rizatriptan 10 mg | 0.3 | 1.3 | 0.6 | 1.0 | 0.0 | 1.6 | 0.3 | 0.6 |
| Telcagepant 280 mg/300 mg | 0.2 | 1.4 | 0.3 | 1.1 | 0.0 | 0.6 | 0.3 | 0.8 |
Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose. (NCT00894556)
Timeframe: 2 hours post dose
| Intervention | attacks (Number) | |
|---|---|---|
| Resulting in PF at 2 hours post dose | Not resulting in PF at 2 hours post dose | |
| Placebo | 12 | 87 |
| Rizatriptan | 46 | 156 |
Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose. (NCT00894556)
Timeframe: 2 hours post dose
| Intervention | attacks (Number) | |
|---|---|---|
| Resulting in PR at 2 hours post dose | Not resulting in PR at 2 hours post dose | |
| Placebo | 21 | 78 |
| Rizatriptan | 102 | 100 |
Level of functional disability was assessed on a paper diary by the participants. Level of functional disability was rated as: normal, mildly impaired, severely impaired, or unable to do activities, requires bedrest. Functional disability ratings was dichotomized to Normal and Not Normal (mildly impaired, severely impaired, or unable to do activities, requires bedrest) for analysis. (NCT00812006)
Timeframe: 2 hours post dose
| Intervention | Attacks (Number) | |
|---|---|---|
| Resulting in NRFD at 2 hours post dose | Not resulting in NRFD at 2 hours post dose | |
| Placebo | 16 | 77 |
| Rizatriptan | 85 | 108 |
Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose. (NCT00812006)
Timeframe: 2 hours post dose
| Intervention | Attacks (Number) | |
|---|---|---|
| Resulting in PF 2 hours post dose | Not resulting in PF 2 hours post dose | |
| Placebo | 9 | 84 |
| Rizatriptan | 74 | 119 |
Pain severity was rated by the participants in a paper diary. Pain severity rating scale : 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose. (NCT00812006)
Timeframe: 2 hours post dose
| Intervention | Attacks (Number) | |
|---|---|---|
| Resulting in PR at 2 hours post dose | Not resulting in PR at 2 hours post dose | |
| Placebo | 21 | 72 |
| Rizatriptan | 105 | 88 |
24-hour sustained pain relief (defined as pain relief at 2 hours post dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the respective period after dosing with the blinded study medication. (NCT00812006)
Timeframe: 2 - 24 hours post dose
| Intervention | Attacks (Number) | |
|---|---|---|
| Resulting in SPR 2-24 hours post dose | Not resulting in SPR 2-24 hours post dose | |
| Placebo | 12 | 81 |
| Rizatriptan | 67 | 126 |
Patient satisfaction was assessed on a paper diary by the participants. Level of satisfaction was rated as: completely satisfied, very satisfied, somewhat satisfied, neither satisfied nor dissatisfied, somewhat dissatisfied, very dissatisfied, or completely dissatisfied. The overall 24-hour assessment of study medication was dichotomized to Satisfaction (completely satisfied, very satisfied, somewhat satisfied) and Non-satisfaction (neither satisfied nor dissatisfied, somewhat dissatisfied, very dissatisfied, or completely dissatisfied) for analysis. (NCT00812006)
Timeframe: 24 hours post dose
| Intervention | Attacks (Number) | |
|---|---|---|
| Resulting in TS at 24 hours post dose | Not resulting in TS at 24 hours post dose | |
| Placebo | 31 | 62 |
| Rizatriptan | 117 | 76 |
Preliminary pharmacokinetics data; Apparent half-life (t½) (NCT00604812)
Timeframe: 24 Hours
| Intervention | Hours (Mean) |
|---|---|
| Panel A Rizatriptan | 1.3 |
| Panel B Rizatriptan | 1.6 |
| Panel C Rizatriptan | 1.6 |
Preliminary pharmacokinetics data; Maximum concentration (Cmax); i.e, highest concentration of drug achieved (NCT00604812)
Timeframe: 24 Hours
| Intervention | ng/mL (Mean) |
|---|---|
| Panel A Rizatriptan | 24.6 |
| Panel B Rizatriptan | 25.0 |
| Panel C Rizatriptan | 18.4 |
Preliminary pharmacokinetics data; Time to maximum concentration (Tmax); i.e., amount of time required to reach maximum concentration (NCT00604812)
Timeframe: 24 Hours
| Intervention | Hours (Median) |
|---|---|
| Panel A Rizatriptan | 1.0 |
| Panel B Rizatriptan | 1.5 |
| Panel C Rizatriptan | 1.3 |
Preliminary pharmacokinetics data; Area Under the Curve (AUC(0-∞)); i.e., area under the concentration-time plot (NCT00604812)
Timeframe: 24 Hours
| Intervention | ng hr/mL (Mean) |
|---|---|
| Panel A Rizatriptan | 59.4 |
| Panel B Rizatriptan | 84.0 |
| Panel C Rizatriptan | 67.93 |
All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram) and laboratory safety tests (hematology/blood chemistry/urinalysis) (NCT00604812)
Timeframe: 24 Hours
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Serious Adverse Events | Non-Serious Adverse Events | No Adverse Events Reported | |
| Placebo | 0 | 3 | 4 |
| Rizatriptan 10 mg | 0 | 7 | 7 |
| Rizatriptan 5 mg | 0 | 3 | 7 |
Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain freedom was defined as a reduction in severity from a rating of 3, 4 or 5 (moderate or severe pain) at the Stage 2 baseline (15 minutes post Stage 1 dose) to a rating of 1 (no pain) at 2 hours post Stage 2 dose. Missing data were imputed by carrying forward the preceding Stage 2 pain intensity values. Missing Stage 2 baseline values were imputed by carrying forward the Stage 1 baseline value, if available. (NCT01001234)
Timeframe: 2 hours post Stage 2 dose
| Intervention | participants (Number) | |
|---|---|---|
| 2-hour pain freedom | No 2-hour pain freedom | |
| Placebo | 63 | 223 |
| Rizatriptan | 87 | 197 |
Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain freedom was defined as a reduction in severity from a rating of 3, 4 or 5 (moderate or severe pain) at the Stage 2 baseline (15 minutes post Stage 1 dose) to a rating of 1 (no pain) at 2 hours post Stage 2 dose. Missing data were imputed by carrying forward the preceding Stage 2 pain intensity values. Missing Stage 2 baseline values were imputed by carrying forward the Stage 1 baseline value, if available. (NCT01001234)
Timeframe: 2 hours post Stage 2 dose
| Intervention | participants (Number) | |
|---|---|---|
| 2-hour pain freedom | No 2-hour pain freedom | |
| Placebo | 94 | 294 |
| Rizatriptan | 126 | 256 |
Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain relief was defined as a reduction in severity from a rating of 3, 4 or 5 (moderate or severe pain) at the Stage 2 baseline (15 minutes post Stage 1 dose) to a rating of 2 or 1 (mild or no pain) at 2 hours post Stage 2 dose. Missing data were imputed by carrying forward the preceding Stage 2 pain intensity values. Missing Stage 2 baseline values were imputed by carrying forward the Stage 1 baseline value, if available. (NCT01001234)
Timeframe: 2 hours post Stage 2 dose
| Intervention | participants (Number) | |
|---|---|---|
| 2-hour pain relief | No 2-hour pain relief | |
| Placebo | 147 | 139 |
| Rizatriptan | 167 | 117 |
Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain relief was defined as a reduction in severity from a rating of 3, 4 or 5 (moderate or severe pain) at the Stage 2 baseline (15 minutes post Stage 1 dose) to a rating of 2 or 1 (mild or no pain) at 2 hours post Stage 2 dose. Missing data were imputed by carrying forward the preceding Stage 2 pain intensity values. Missing Stage 2 baseline values were imputed by carrying forward the Stage 1 baseline value, if available. (NCT01001234)
Timeframe: 2 hours post Stage 2 dose
| Intervention | participants (Number) | |
|---|---|---|
| 2-hour pain relief | No 2-hour pain relief | |
| Placebo | 204 | 184 |
| Rizatriptan | 220 | 162 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration. Participants who discontinued due to an AE occurring within 14 days post dose are counted in this summary. (NCT01004263)
Timeframe: Up to 14 days post dose
| Intervention | participants (Number) |
|---|---|
| Rizatriptan | 14 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration. Participants who discontinued due to an AE occurring within 24 hours post dose are counted in this summary. (NCT01004263)
Timeframe: Up to 24 hours post dose
| Intervention | participants (Number) |
|---|---|
| Rizatriptan | 4 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration. Participants reported AEs in a diary and these were collected by the study site at visits at 1, 2, 3, 4, 6, 9, and 12 months after Screening visit. Participants with an AE occurring within 24 hours after any dose administered during the study are counted once in this summary. (NCT01004263)
Timeframe: Up to 24 hours post dose
| Intervention | participants (Number) |
|---|---|
| Rizatriptan | 322 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration. Participants reported AEs in a diary and these were collected by the study site at visits at 1, 2, 3, 4, 6, 9, and 12 months after Screening visit. AEs were assessed in a phone contact 14 days after the last dose of study medication. Participants with an AE occurring within 14 days after any dose administered during the study are counted once in this summary. (NCT01004263)
Timeframe: Up to 14 days post dose
| Intervention | participants (Number) |
|---|---|
| Rizatriptan | 400 |
Pain intensity was assessed using a 5-Face Pain Scale ranging from 1=no pain to 5=very bad pain. Pain freedom (PF) was defined as a reduction in severity from a rating of 5, 4, 3 or 2 (mild, moderate or severe pain) before the dose to a rating of 1 (no pain) at 2 hours after dosing. Pain intensity ratings were reported in diaries returned at visits at 1, 2, 3, 4, 6, 9, and 12 months after Screening visit. PF at 2 hours was summarized as follows: the percentage of treated attacks with PF at 2 hours was calculated for each patient first, then the mean across all patients was calculated. (NCT01004263)
Timeframe: 2 hours post dose
| Intervention | percentage of participant's attacks (Mean) |
|---|---|
| Rizatriptan | 46.3 |
Participants reporting the absence of nausea at 2 hours post treatment. Absence or presence of nausea was recorded by the participants in an electronic diary. Absence is defined as no nausea at 2 hours post-treatment. (NCT00250458)
Timeframe: At 2 hours after treatment
| Intervention | Participants (Number) | |
|---|---|---|
| No Nausea at 2 Hours | Nausea at 2 Hours | |
| Placebo | 57 | 35 |
| Rizatriptan 10 mg | 130 | 55 |
Participants reporting pain relief defined as a reduction of pain severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment. (NCT00250458)
Timeframe: 2 hours after treatment
| Intervention | Participants (Number) | |
|---|---|---|
| 2-Hour Pain Relief | No 2-Hour Pain Relief | |
| Placebo | 50 | 42 |
| Rizatriptan 10 mg | 129 | 56 |
64 reviews available for rizatriptan and Abdominal Migraine
| Article | Year |
|---|---|
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
Topics: Amino Acid Sequence; Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Recep | 2014 |
The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine: A Systematic Review.
Topics: Adolescent; Child; Headache; Humans; Migraine Disorders; Naproxen; Sumatriptan; Tryptamines | 2023 |
[Placebo and nocebo : How can they be used or avoided?]
Topics: Analgesics; Ethics, Medical; Humans; Migraine Disorders; Nocebo Effect; Physician-Patient Relations; | 2017 |
Rizatriptan-Induced Colonic Ischemia: A Case Report and Literature Review.
Topics: Colectomy; Colonic Diseases; Computed Tomography Angiography; Humans; Infarction; Male; Mesenteric I | 2018 |
Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies.
Topics: Carbazoles; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Migraine Disorders; Oxazo | 2013 |
The efficacy of triptans in childhood and adolescence migraine.
Topics: Adolescent; Analgesics; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, C | 2013 |
[Rizatriptan: experience after 15 years of clinical use].
Topics: Adolescent; Adult; Biological Availability; Child; Clinical Trials as Topic; Drug Approval; Humans; | 2013 |
Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis.
Topics: Acute Disease; Azepines; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Imidazoles; M | 2015 |
Oral triptans in children and adolescents: an update.
Topics: Acetaminophen; Administration, Oral; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Dos | 2015 |
Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cross-Over Studies; Double-Blind Method; Drug T | 2016 |
Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen; Migraine Disorders; Oxazolidinones; Pyrr | 2016 |
Ten years of rizatriptan: from development to clinical science and future directions.
Topics: Animals; Drug Design; Drug Evaluation; Drug Therapy; History, 20th Century; History, 21st Century; H | 2009 |
Acute migraine treatment with rizatriptan in real world settings - focusing on treatment strategy, effectiveness, and behavior.
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Outcome Assessment, Health Care; Patient Selec | 2009 |
Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis.
Topics: Double-Blind Method; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Migraine Disorders; Pa | 2010 |
Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database.
Topics: Adult; Clinical Trials, Phase III as Topic; Databases, Factual; Endpoint Determination; Female; Huma | 2011 |
Sumatriptan (intranasal route of administration) for acute migraine attacks in adults.
Topics: Acute Disease; Administration, Intranasal; Adult; Dihydroergotamine; Female; Humans; Male; Migraine | 2012 |
Mechanisms of action of the 5-HT1B/1D receptor agonists.
Topics: Carbazoles; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Receptor | 2002 |
[Treatment of migraine in patients with hypertension and ischemic heart disease].
Topics: Adjuvants, Pharmaceutic; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Carbazol | 2002 |
Spotlight on rizatriptan in migraine.
Topics: Animals; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Serotonin Receptor Agoni | 2002 |
Rizatriptan: pharmacological differences from sumatriptan and clinical results.
Topics: Administration, Oral; Humans; Migraine Disorders; Patient Satisfaction; Recurrence; Serotonin Recept | 2001 |
Comparative aspects of triptans in treating migraine.
Topics: Carbazoles; Cardiovascular Diseases; Humans; Indoles; Migraine Disorders; Oxazolidinones; Patient Sa | 2001 |
Newer formulations of the triptans: advances in migraine management.
Topics: Analgesics; Area Under Curve; Chemistry, Pharmaceutical; Humans; Migraine Disorders; Oxazolidinones; | 2003 |
Triptans for treatment of acute pediatric migraine: a systematic literature review.
Topics: Acute Disease; Administration, Intranasal; Administration, Oral; Child; Clinical Trials as Topic; Hu | 2003 |
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
Topics: Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; | 2004 |
[Recent progress in therapy for migraine headache].
Topics: Anticonvulsants; Botulinum Toxins; Calcitonin Gene-Related Peptide; Central Nervous System; Clinical | 2004 |
A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine.
Topics: Acute Disease; Administration, Oral; Clinical Trials as Topic; Drug Interactions; Humans; Migraine D | 2004 |
[Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance].
Topics: Clinical Trials as Topic; Humans; Meningeal Arteries; Migraine Disorders; Quality of Life; Receptor, | 2004 |
[Meta-analysis of triptan treatment in migraine].
Topics: Carbazoles; Evidence-Based Medicine; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidine | 2004 |
[Side effects of triptans].
Topics: Central Nervous System; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorders; Nause | 2004 |
Migraine headache.
Topics: Acute Disease; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Dicl | 2003 |
Migraine headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Ergotamine; Humans; Ibuprofen; Indoles; Migrain | 2004 |
Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
Topics: Caffeine; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Economics, Pharmaceut | 2005 |
The treatment of pediatric migraine.
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Antidepressive Agents; Antiemetics; Biofeedback, Psych | 2005 |
Rizatriptan in migraine.
Topics: Dose-Response Relationship, Drug; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; E | 2005 |
Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
Topics: Economics, Pharmaceutical; Humans; Migraine Disorders; Serotonin 5-HT1 Receptor Agonists; Serotonin | 2005 |
[Triptanes in the treatment of migraine. A review based on three Cochrane reviews].
Topics: Acute Disease; Administration, Oral; Dose-Response Relationship, Drug; Humans; Migraine Disorders; P | 2006 |
Acute treatment of paediatric migraine: a meta-analysis of efficacy.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; | 2008 |
A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future.
Topics: Adult; Child; Drug Therapy, Combination; Humans; Migraine Disorders; Randomized Controlled Trials as | 2008 |
Acute treatment and prevention of menstrually related migraine headache: evidence-based review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Double-Blind Method; Estrogens; Evidence-Based | 2008 |
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
Topics: Acute Disease; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Vasospasm; Drug Des | 1999 |
Rizatriptan: a review of its efficacy in the management of migraine.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Migraine Disorders; Serotonin Receptor Agoni | 1999 |
The scientific basis of medication choice in symptomatic migraine treatment.
Topics: Acute Disease; Choice Behavior; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorder | 1999 |
Newer intranasal migraine medications.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Non-Narcotic; Clinical Trials as Topic | 2000 |
[Rizatriptan].
Topics: Dose-Response Relationship, Drug; Drug Tolerance; Humans; Migraine Disorders; Serotonin Receptor Ago | 2000 |
Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Topics: Acute Disease; Carbazoles; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidine | 2000 |
Rizatriptan in the treatment of migraine.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Humans; Migraine Disorders; Randomized Contr | 1999 |
Pharmacology and potential mechanisms of action of rizatriptan.
Topics: Brain; Humans; Migraine Disorders; Muscle, Smooth, Vascular; Receptor, Serotonin, 5-HT1B; Receptor, | 2000 |
Rizatriptan in acute treatment of migraine: update on new comparative data.
Topics: Acute Disease; Clinical Trials as Topic; Humans; Migraine Disorders; Serotonin Receptor Agonists; Tr | 2000 |
Safety and tolerability of rizatriptan.
Topics: Adverse Drug Reaction Reporting Systems; Clinical Trials as Topic; Humans; Migraine Disorders; Serot | 2000 |
Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Triazoles; Tryptamines | 2000 |
The use of rizatriptan in the treatment of acute, multiple migraine attacks.
Topics: Acute Disease; Humans; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; Triazoles; Trypt | 2000 |
Impact of migraine and migraine therapy on productivity and quality of life.
Topics: Humans; Migraine Disorders; Quality of Life; Serotonin Receptor Agonists; Surveys and Questionnaires | 2000 |
New abortive agents for the treatment of migraine.
Topics: Clinical Trials as Topic; Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperid | 2001 |
Evidence-based analysis of a migraine treatment drug comparison trial.
Topics: Adult; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Migraine Disorders; Sumatr | 2000 |
[Current topics: expectation for new triptans].
Topics: Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Serotonin Receptor A | 2001 |
Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials.
Topics: Adult; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Male; Migraine Diso | 2001 |
Establishing a standard of speed for assessing the efficacy of the serotonin(1B/1D) agonists (triptans).
Topics: Analgesics, Non-Narcotic; Carbazoles; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; | 2001 |
What matters is not the differences between triptans, but the differences between patients.
Topics: Humans; Migraine Disorders; Oxazolidinones; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Try | 2001 |
Comparison of rizatriptan and other triptans on stringent measures of efficacy.
Topics: Administration, Oral; Humans; Indoles; Migraine Disorders; Oxazolidinones; Patient Satisfaction; Pip | 2001 |
Rizatriptan for acute migraine.
Topics: Acute Disease; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Serotonin Receptor | 2001 |
Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons.
Topics: Adolescent; Adult; Aged; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; M | 2001 |
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
Topics: Acute Disease; Administration, Oral; Humans; Indoles; Migraine Disorders; Pyrrolidines; Randomized C | 2001 |
Acute treatment of migraine and the role of triptans.
Topics: Acute Disease; Blood Flow Velocity; Carbazoles; Clinical Trials as Topic; Drug Administration Routes | 2001 |
Rizatriptan: an update of its use in the management of migraine.
Topics: Administration, Oral; Adolescent; Adult; Animals; Biological Availability; Databases, Bibliographic; | 2002 |
78 trials available for rizatriptan and Abdominal Migraine
| Article | Year |
|---|---|
Frovatriptan and rizatriptan economic EVAluation: the FREEVA study.
Topics: Adult; Analgesics; Carbazoles; Cost-Benefit Analysis; Cross-Over Studies; Double-Blind Method; Femal | 2013 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Altered placebo and drug labeling changes the outcome of episodic migraine attacks.
Topics: Drug Labeling; Endpoint Determination; Humans; Migraine Disorders; Pain Measurement; Placebos; Treat | 2014 |
Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.
Topics: Adult; Carbazoles; Cross-Over Studies; Double-Blind Method; Female; Half-Life; Humans; Male; Middle | 2014 |
Theory-based analysis of clinical efficacy of triptans using receptor occupancy.
Topics: Humans; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Serotonin 5-HT1 Receptor Agon | 2014 |
Clinicopharmacological comparative study of rizatriptan versus conventional therapy in migraine.
Topics: Acetaminophen; Adolescent; Adult; Aged; Alprazolam; Analgesics, Non-Narcotic; Female; Flunarizine; H | 2014 |
[Comparison of triptans, NSAID and combination in migraine attack treatment].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Humans; Male; Mig | 2016 |
Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment.
Topics: Acetaminophen; Acute Disease; Adult; Aged; Analgesics, Non-Narcotic; Double-Blind Method; Drug Thera | 2008 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; Opioid-Related Di | 2009 |
Migraine treatment with rizatriptan and almotriptan: a crossover study.
Topics: Adult; Cross-Over Studies; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain Measurement; | 2009 |
Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Early Diagnosis; Fem | 2009 |
Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Early Diagnosis; Fem | 2009 |
Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Early Diagnosis; Fem | 2009 |
Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Early Diagnosis; Fem | 2009 |
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs.
Topics: Adult; Double-Blind Method; Female; Humans; Migraine Disorders; Motion Sickness; Serotonin Receptor | 2009 |
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
Topics: Acute Disease; Adult; Biomarkers; Calcitonin Gene-Related Peptide; Drug Resistance; Female; Humans; | 2009 |
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
Topics: Acute Disease; Adult; Biomarkers; Calcitonin Gene-Related Peptide; Drug Resistance; Female; Humans; | 2009 |
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
Topics: Acute Disease; Adult; Biomarkers; Calcitonin Gene-Related Peptide; Drug Resistance; Female; Humans; | 2009 |
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
Topics: Acute Disease; Adult; Biomarkers; Calcitonin Gene-Related Peptide; Drug Resistance; Female; Humans; | 2009 |
A comparison of migraine patients with and without allodynic symptoms.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Double-Blind Method; Femal | 2009 |
A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine.
Topics: Adolescent; Adult; Aged; Carbazoles; Double-Blind Method; Drug Administration Schedule; Female; Huma | 2011 |
Rizatriptan reduces vestibular-induced motion sickness in migraineurs.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Motion Sickness; | 2011 |
Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
Topics: Adult; Aged; Azepines; Calcitonin Gene-Related Peptide Receptor Antagonists; Double-Blind Method; En | 2011 |
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Di | 2011 |
Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan.
Topics: Acute Disease; Adolescent; Adult; Aged; Carbazoles; Cross-Over Studies; Double-Blind Method; Female; | 2011 |
Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis.
Topics: Acute Disease; Adolescent; Adult; Aged; Disability Evaluation; Double-Blind Method; Female; Fructose | 2012 |
Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.
Topics: Adolescent; Child; Double-Blind Method; Female; Headache; Humans; Male; Migraine Disorders; Triazole | 2012 |
Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial.
Topics: Adult; Autonomic Nervous System Diseases; Chi-Square Distribution; Double-Blind Method; Female; Func | 2012 |
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Serotonin Receptor | 2012 |
Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs.
Topics: Adolescent; Child; Female; Humans; Male; Migraine Disorders; Serotonin Receptor Agonists; Triazoles; | 2013 |
Determinants of migraine-specific quality of life.
Topics: Adult; Humans; Migraine Disorders; Multicenter Studies as Topic; Quality of Life; Randomized Control | 2002 |
Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
Topics: Adolescent; Adult; Aged; Caffeine; Cross-Over Studies; Double-Blind Method; Drug Combinations; Ergot | 2003 |
[Satisfaction and recovery of normal activity with rizatriptan 10 mg. Results from the open, prospective, observational 4M study].
Topics: Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain Measurement; Patient Satisfaction | 2002 |
Real-world experiences in migraine therapy with rizatriptan.
Topics: Acute Disease; Adult; Female; Follow-Up Studies; Humans; Male; Middle Aged; Migraine Disorders; Pati | 2003 |
Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness.
Topics: Adolescent; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Ergot Alkaloids; Femal | 2003 |
Rizatriptan RPD for severe migraine in the emergency department--a multicenter study.
Topics: Adult; Emergency Medical Services; Female; Humans; Male; Middle Aged; Migraine Disorders; Treatment | 2003 |
Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Female; Humans; Male; Middle Aged; Migraine Disorders | 2003 |
Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Sumatripta | 2004 |
Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhi | 2004 |
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
Topics: Acute Disease; Adolescent; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Recurrence | 2004 |
Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
Topics: Acute Disease; Adolescent; Adult; Analgesics; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2004 |
Pharmacokinetics of rizatriptan tablets during and between migraine attacks.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Migrai | 1999 |
Rizatriptan does not change cerebral blood flow velocity during migraine attacks.
Topics: Adult; Cerebral Cortex; Female; Functional Laterality; Humans; Laser-Doppler Flowmetry; Male; Middle | 2005 |
Multiple attack study on the available triptans in Italy versus placebo.
Topics: Adult; Female; Humans; Indoles; Italy; Male; Middle Aged; Migraine Disorders; Oxazolidinones; Pyrrol | 2005 |
Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Patient Satisfaction | 2005 |
Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorder | 2006 |
Clinical efficacy of rizatriptan for patients with migraine: efficacy of drug therapy for migraine accompanied by tension headache-like symptoms, focusing on neck stiffness.
Topics: Adult; Female; Humans; Male; Migraine Disorders; Muscular Diseases; Neck Muscles; Serotonin Receptor | 2005 |
Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders | 2006 |
Efficacy of Rizatriptan 10 mg administered early in a migraine attack.
Topics: Acute Disease; Adult; Female; Humans; Male; Medical Records; Migraine Disorders; Patient Satisfactio | 2006 |
Efficacy of Rizatriptan 10 mg administered early in a migraine attack.
Topics: Acute Disease; Adult; Female; Humans; Male; Medical Records; Migraine Disorders; Patient Satisfactio | 2006 |
Efficacy of Rizatriptan 10 mg administered early in a migraine attack.
Topics: Acute Disease; Adult; Female; Humans; Male; Medical Records; Migraine Disorders; Patient Satisfactio | 2006 |
Efficacy of Rizatriptan 10 mg administered early in a migraine attack.
Topics: Acute Disease; Adult; Female; Humans; Male; Medical Records; Migraine Disorders; Patient Satisfactio | 2006 |
Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Drug Combinations; Female; Gastrointestinal Agents; Gastropa | 2006 |
Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Topics: Adult; Cross-Over Studies; Female; Humans; Male; Migraine Disorders; Prospective Studies; Serotonin | 2006 |
A randomized trial of rizatriptan in migraine attacks in children.
Topics: Administration, Oral; Adolescent; Ambulatory Care; Child; Cross-Over Studies; Dose-Response Relation | 2006 |
Comparative sensitivity of stopwatch methodology and conventional pain assessment measures for detecting early response to triptans in migraine: results of a randomized, open-label pilot study.
Topics: Adult; Analysis of Variance; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain Measurement | 2006 |
Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Female; Humans; Male; Meta-Analys | 2007 |
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.
Topics: Acute Disease; Adolescent; Adult; Analgesics; Comorbidity; Double-Blind Method; Female; Humans; Mens | 2007 |
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.
Topics: Acute Disease; Adolescent; Adult; Analgesics; Comorbidity; Double-Blind Method; Female; Humans; Mens | 2007 |
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.
Topics: Acute Disease; Adolescent; Adult; Analgesics; Comorbidity; Double-Blind Method; Female; Humans; Mens | 2007 |
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.
Topics: Acute Disease; Adolescent; Adult; Analgesics; Comorbidity; Double-Blind Method; Female; Humans; Mens | 2007 |
Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Ibuprofen; Male; Migr | 2007 |
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.
Topics: Adult; Comorbidity; Double-Blind Method; Female; Headache; Humans; Hyperalgesia; Male; Migraine Diso | 2007 |
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.
Topics: Adult; Comorbidity; Double-Blind Method; Female; Headache; Humans; Hyperalgesia; Male; Migraine Diso | 2007 |
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.
Topics: Adult; Comorbidity; Double-Blind Method; Female; Headache; Humans; Hyperalgesia; Male; Migraine Diso | 2007 |
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.
Topics: Adult; Comorbidity; Double-Blind Method; Female; Headache; Humans; Hyperalgesia; Male; Migraine Diso | 2007 |
Traditional acupuncture in migraine: a controlled, randomized study.
Topics: Acupuncture Therapy; Adult; Female; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Migrai | 2008 |
Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies.
Topics: Adult; Disability Evaluation; Double-Blind Method; Drug Evaluation; Female; Humans; Menstruation Dis | 2008 |
Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies.
Topics: Adult; Disability Evaluation; Double-Blind Method; Drug Evaluation; Female; Humans; Menstruation Dis | 2008 |
Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies.
Topics: Adult; Disability Evaluation; Double-Blind Method; Drug Evaluation; Female; Humans; Menstruation Dis | 2008 |
Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies.
Topics: Adult; Disability Evaluation; Double-Blind Method; Drug Evaluation; Female; Humans; Menstruation Dis | 2008 |
Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Nausea; | 2008 |
Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine.
Topics: Adolescent; Adult; Clinical Protocols; Disability Evaluation; Double-Blind Method; Female; Humans; M | 2008 |
Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine.
Topics: Adolescent; Adult; Clinical Protocols; Disability Evaluation; Double-Blind Method; Female; Humans; M | 2008 |
Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine.
Topics: Adolescent; Adult; Clinical Protocols; Disability Evaluation; Double-Blind Method; Female; Humans; M | 2008 |
Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine.
Topics: Adolescent; Adult; Clinical Protocols; Disability Evaluation; Double-Blind Method; Female; Humans; M | 2008 |
Pilot study of MK-462 in migraine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 1996 |
Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Mig | 1996 |
Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist.
Topics: Administration, Oral; Adult; Analysis of Variance; Blood Pressure; Double-Blind Method; Heart Rate; | 1997 |
Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine.
Topics: Acute Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Logistic Model | 1997 |
Improvement in migraine-specific quality of life in a clinical trial of rizatriptan.
Topics: Adult; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; | 1997 |
Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migr | 1998 |
A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Female; Humans; Male; Middle Aged | 1998 |
Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females.
Topics: Adult; Analysis of Variance; Cross-Over Studies; Dizziness; Female; Humans; Injections, Intravenous; | 1998 |
Validation of a migraine work and productivity loss questionnaire for use in migraine studies.
Topics: Absenteeism; Adult; Disability Evaluation; Female; Humans; Male; Middle Aged; Migraine Disorders; Re | 1999 |
Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dosage Forms; Double-Blind Method; Female; Humans; Ma | 1999 |
Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Male; Middle | 1999 |
Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial.
Topics: Administration, Oral; Cross-Over Studies; Drug Resistance; Humans; Migraine Disorders; Oxazoles; Oxa | 2000 |
Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group.
Topics: Adult; Disability Evaluation; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Oxazoli | 2000 |
Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.
Topics: Adult; Analysis of Variance; Blood Flow Velocity; Blood Pressure; Brachial Artery; Carotid Artery, C | 2000 |
Within-patient consistency of response of rizatriptan for treating migraine.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2000 |
Work and productivity loss in the rizatriptan multiple attack study.
Topics: Absenteeism; Adult; Efficiency; Female; Humans; Male; Middle Aged; Migraine Disorders; Multicenter S | 2000 |
Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes.
Topics: Adult; Female; Humans; Male; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; Time Facto | 2001 |
Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Female; Humans; Male; Middle Aged | 2001 |
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2001 |
Long-term efficacy and tolerability of rizatriptan wafers in migraine.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Pain Measurement; Serotonin Re | 2001 |
Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine.
Topics: Adult; Cross-Over Studies; Female; Humans; Male; Migraine Disorders; Serotonin Receptor Agonists; Su | 2001 |
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Placebos; Serotoni | 2002 |
Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Therapy, | 2002 |
The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.
Topics: Adult; Arteries; Cross-Over Studies; Double-Blind Method; Drug Combinations; Ergotamine; Heart Rate; | 2002 |
90 other studies available for rizatriptan and Abdominal Migraine
| Article | Year |
|---|---|
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
Topics: Acute Disease; Administration, Oral; Animals; Biological Availability; Calcium; Carboxylic Acids; Ce | 2002 |
Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding.
Topics: Adult; Breast Feeding; Female; Humans; Infant; Infant, Newborn; Migraine Disorders; Milk, Human; Oxa | 2021 |
Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies.
Topics: Carbazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Double-Blind Method; Female; Humans; | 2013 |
[Expectation is one half of therapy].
Topics: Analgesics; Culture; Humans; Migraine Disorders; Placebo Effect; Randomized Controlled Trials as Top | 2014 |
Effects of rizatriptan on the expression of calcitonin gene-related peptide and cholecystokinin in the periaqueductal gray of a rat migraine model.
Topics: Animals; Calcitonin Gene-Related Peptide; Cholecystokinin; Female; Male; Migraine Disorders; Periaqu | 2015 |
Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation.
Topics: Administration, Oral; Animals; Biological Availability; Drug Delivery Systems; Drug Liberation; Drug | 2016 |
Multivariate Optimization of Rizatriptan Benzoate-Loaded Solid Lipid Nanoparticles for Brain Targeting and Migraine Management.
Topics: Administration, Oral; Animals; Brain; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug C | 2017 |
Comparison of rizatriptan and sumatriptan.
Topics: Humans; Migraine Disorders; Patient Satisfaction; Serotonin Receptor Agonists; Sumatriptan; Time Fac | 1999 |
Elastic liposomal formulation for sustained delivery of antimigraine drug: in vitro characterization and biological evaluation.
Topics: Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Elasticity; Hyperalgesia; Liposomes | 2008 |
10 years of rizatriptan.
Topics: History, 20th Century; History, 21st Century; Humans; Migraine Disorders; Serotonin Receptor Agonist | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo | 2009 |
[Utilizing the strength(s) of rizatriptan 10 mg: cost effective against migraine attacks].
Topics: Administration, Sublingual; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Hum | 2009 |
Rizatriptan. Convenience and consistency.
Topics: Acute Disease; Administration, Oral; Humans; Migraine Disorders; Serotonin Receptor Agonists; Tablet | 2000 |
Evaluating the efficacy of migraine therapy.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Time Factors; Treatment Outcom | 2000 |
Rizatriptan. Comparative trial results.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazolidinones; Pipe | 2000 |
A study of triggers of migraine in India.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diet; Disability Evaluation; Eating; Fem | 2010 |
Rizatriptan induced acute on top of chronic ischemic colitis.
Topics: Colitis, Ischemic; Colonoscopy; Diagnosis, Differential; Female; Humans; Middle Aged; Migraine Disor | 2009 |
Arterial spin-labeled MRI study of migraine attacks treated with rizatriptan.
Topics: Adult; Cerebral Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Functional Lateral | 2010 |
Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007.
Topics: Adolescent; Adult; Age Factors; Child; Drug Approval; Female; Finland; Humans; Male; Migraine Disord | 2011 |
[Rizatriptan-induced liver toxicity. Report of a case].
Topics: Adolescent; Chemical and Drug Induced Liver Injury; Female; Humans; Immune Complex Diseases; Jaundic | 2013 |
Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment.
Topics: Analgesics; Animals; Blotting, Western; Botulinum Toxins, Type A; Calcitonin Gene-Related Peptide; C | 2013 |
Comparison of rizatriptan and other triptans on stringent measures of efficacy.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Triazoles; Tryptamines | 2002 |
Comparison of rizatriptan and other triptans on stringent measures of efficacy.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Triazoles; Tryptamines | 2002 |
Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Female; Humans; Indoles; Male; Middle Aged; Migraine | 2002 |
Sum of Pain Intensity Differences (SPID) in migraine trials. A comment based on four rizatriptan trials.
Topics: Humans; Migraine Disorders; Outcome Assessment, Health Care; Pain Measurement; Serotonin Receptor Ag | 2002 |
Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data.
Topics: Administration, Oral; Adult; Female; Humans; Menstruation; Migraine Disorders; Retrospective Studies | 2002 |
Rizatriptan 5mg is not efficacious for migraine in adolescents.
Topics: Acute Disease; Adolescent; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Seroto | 2002 |
[New onset headache. Which patients should be sent for CT imaging?].
Topics: Acute Disease; Brain Diseases; Diagnosis, Differential; Drug Administration Schedule; Headache; Huma | 2002 |
[New therapeutic recommendations for severe migraine. High beginning dosage rather than slow dosage increase].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Migraine Disorders; Serotoni | 2003 |
Investigation of the effects of naratriptan, rizatriptan, and sumatriptan on jugular venous oxygen saturation in anesthetized pigs: implications for their mechanism of acute antimigraine action.
Topics: Anesthesia; Animals; Blood Gas Analysis; Hemodynamics; Indoles; Jugular Veins; Male; Migraine Disord | 2003 |
[Highly selective beginning. Associated symptoms and side effects in retrospect].
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Migraine D | 2003 |
Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.
Topics: Acute Disease; Cost-Benefit Analysis; Decision Support Techniques; Female; Health Care Costs; Health | 2003 |
Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
Topics: Administration, Oral; Adolescent; Adult; Humans; Injections; Middle Aged; Migraine Disorders; Oxazol | 2004 |
Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model.
Topics: Absenteeism; Adult; Cost-Benefit Analysis; Efficiency; Employer Health Costs; Female; Humans; Male; | 2004 |
[It impairs quality of life and work time. Migraine therapy should not be left to the patients!].
Topics: Absenteeism; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Ergot Alkaloids; Ger | 2003 |
TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management.
Topics: Administration, Oral; Adult; Data Collection; Decision Support Techniques; Dose-Response Relationshi | 2004 |
[It's possible to influence prescriptions patterns by producer-independent information].
Topics: Community Health Centers; Drug Information Services; Drug Prescriptions; Follow-Up Studies; Guidelin | 2004 |
Evaluating triptan usage: a rebuttal.
Topics: Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Triazole | 2004 |
[Modern migraine therapy].
Topics: Absenteeism; Adult; Cross-Sectional Studies; Drug Utilization; Female; Germany; Humans; Migraine Dis | 2004 |
The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective.
Topics: Absenteeism; Adult; Costs and Cost Analysis; Counseling; Efficiency; Female; Follow-Up Studies; Huma | 2004 |
Correlation between lipophilicity and triptan outcomes.
Topics: Central Nervous System Diseases; Chemical Phenomena; Chemistry, Physical; Humans; Indoles; Migraine | 2005 |
[Migraine therapy--rapid and effective].
Topics: Clinical Trials as Topic; Drug Administration Schedule; Humans; Migraine Disorders; Secondary Preven | 2004 |
[Migraine].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Calcium Channel Blockers; Child; Female; Humans; Int | 2004 |
Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat.
Topics: Algorithms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Humans; Mana | 2005 |
An economic evaluation of rizatriptan in the treatment of migraine.
Topics: Canada; Cost-Benefit Analysis; Decision Trees; Humans; Migraine Disorders; Reproducibility of Result | 2005 |
Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders.
Topics: Calcitonin Gene-Related Peptide; Drug Resistance; Humans; Immunoenzyme Techniques; Migraine Disorder | 2006 |
Company reference estimates for productivity loss due to migraine and productivity gains using rizatriptan 10 mg in Germany.
Topics: Absenteeism; Adult; Aged; Cost of Illness; Efficiency; Female; Germany; Humans; Male; Middle Aged; M | 2006 |
[Medical treatment of migraine attacks in the child].
Topics: Acetaminophen; Age Factors; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Ergot Alkalo | 2006 |
Renal infarction during the use of rizatriptan and zolmitriptan: two case reports.
Topics: Adult; Cluster Headache; Humans; Infarction; Kidney; Male; Middle Aged; Migraine Disorders; Oxazolid | 2006 |
Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches.
Topics: Female; Health Maintenance Organizations; Humans; Male; Medical Records Systems, Computerized; Middl | 2006 |
Increasing the effect of triptans in migraine.
Topics: Cross-Over Studies; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Migraine Disorders; | 2006 |
Transient ischemic attack after rizatriptan administration in a liver transplant recipient: a case report.
Topics: Adult; Humans; Ischemic Attack, Transient; Liver Transplantation; Male; Migraine Disorders; Postoper | 2006 |
A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
Topics: Administration, Oral; Cost-Benefit Analysis; Decision Trees; Humans; Italy; Migraine Disorders; Sens | 2006 |
Comment on eletriptan in migraine patients reporting unsatisfactory response to rizatriptan.
Topics: Humans; Migraine Disorders; Patient Satisfaction; Pyrrolidines; Retreatment; Serotonin Receptor Agon | 2007 |
Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.
Topics: Acute Disease; Adult; Cross-Over Studies; Female; Humans; Male; Middle Aged; Migraine Disorders; Mul | 2007 |
Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Glutamic Acid; Headache Disorders; Headache D | 2007 |
[Bonus-malus regulations in the framework of the AVWG guideline-suitable migraine therapy are possible].
Topics: Clinical Trials as Topic; Cross-Over Studies; Drug and Narcotic Control; Germany; Humans; Migraine D | 2007 |
[A new therapeutic principle for migraine].
Topics: Azepines; Calcitonin Gene-Related Peptide; Humans; Imidazoles; Migraine Disorders; Piperazines; Quin | 2008 |
Rizatriptan has central antinociceptive effects against durally evoked responses.
Topics: Action Potentials; Analysis of Variance; Animals; Blood-Brain Barrier; Disease Models, Animal; Dose- | 1997 |
The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.
Topics: Analysis of Variance; Animals; Blood Proteins; Calcitonin Gene-Related Peptide; Disease Models, Anim | 1997 |
Please don't hi-jack "quality of life".
Topics: Humans; Migraine Disorders; Quality of Life; Serotonin Receptor Agonists; Triazoles; Tryptamines | 1998 |
Coronary side-effect potential of current and prospective antimigraine drugs.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Child; Coronary Vessels; Dihydroergotamine; Ergotamine; Fe | 1998 |
Oral migraine drug approved for marketing.
Topics: Administration, Oral; Humans; Migraine Disorders; Serotonin Receptor Agonists; Triazoles; Tryptamine | 1998 |
New "triptans" and other drugs for migraine.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 1998 |
Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.
Topics: Administration, Oral; Area Under Curve; Carbon Radioisotopes; Chromatography, High Pressure Liquid; | 2000 |
Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry.
Topics: Bufotenin; Chromatography, High Pressure Liquid; Humans; Indoles; Mass Spectrometry; Migraine Disord | 2000 |
Rizatriptan tablet versus wafer: patient preference.
Topics: Adult; Dosage Forms; Drug Evaluation; Freeze Drying; Humans; Migraine Disorders; Patient Satisfactio | 2000 |
Rizatriptan in the treatment of menstrual migraine.
Topics: Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Menstrua | 2000 |
Triptans to the rescue: effective therapy for migraine headaches in the workplace.
Topics: Absenteeism; Adult; Cost-Benefit Analysis; Efficiency; Female; Humans; Indoles; Injections, Subcutan | 2000 |
Treatment options for acute migraine.
Topics: Acute Disease; Adult; Female; Humans; Migraine Disorders; Oxazolidinones; Patient Selection; Practic | 2000 |
Determinants of patient satisfaction with migraine therapy.
Topics: Adult; Analgesics; Female; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Patient Satisfacti | 2000 |
Rizatriptan: a new milestone in migraine treatment. Introduction.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Treatment Outcome; Triazoles; Tryptamines | 2000 |
Rizatriptan: a new milestone in migraine treatment. Closing remarks.
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Serotonin Receptor Agonists; Triazoles; Trypta | 2000 |
Newer triptans: emphasis on rizatriptan.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Triazoles; Tryptamines | 2000 |
Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Migraine Disord | 2000 |
Rizatriptan versus usual care in long-term treatment of migraine.
Topics: Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Time Factors; Triazoles; Trypt | 2000 |
[Migraine therapy. Help for the head--without risk for to the heart].
Topics: Hemodynamics; Humans; Migraine Disorders; Serotonin Receptor Agonists; Treatment Outcome; Triazoles; | 2000 |
Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine.
Topics: Administration, Sublingual; Humans; Migraine Disorders; Serotonin Receptor Agonists; Time Factors; T | 2001 |
Effect of rizatriptan in the spectrum of headache.
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Retrospective Studies; Serotonin Receptor Agon | 2001 |
Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study.
Topics: Activities of Daily Living; Adult; Female; Humans; Male; Migraine Disorders; Patient Satisfaction; S | 2001 |
The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
Topics: Anesthesia; Animals; Benzamides; Calcitonin Gene-Related Peptide; Chromans; Dose-Response Relationsh | 2001 |
Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
Topics: Administration, Oral; Adult; Double-Blind Method; Humans; Indoles; Migraine Disorders; Nausea; Oxazo | 2001 |
Migraine MLT-down: an unusual presentation of migraine in patients with aspartame-triggered headaches.
Topics: Adolescent; Adult; Aspartame; Female; Humans; Male; Migraine Disorders; Serotonin Receptor Agonists; | 2001 |
[Therapy of an acute migraine attack. Uniform patient vote for rizatriptan].
Topics: Germany; Humans; Migraine Disorders; Patient Satisfaction; Serotonin Receptor Agonists; Treatment Ou | 2001 |
Evidence-based migraine therapy.
Topics: Evidence-Based Medicine; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Triaz | 2001 |
Treatment of migraine with rizatriptan: when to take the medication.
Topics: Drug Administration Schedule; Humans; Migraine Disorders; Prospective Studies; Serotonin Receptor Ag | 2002 |
Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain.
Topics: Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperidines; Prospective Studies; | 2002 |
[New meta-analysis of triptanes. Concrete help, so the choice doesn't become overwhelming].
Topics: Humans; Meta-Analysis as Topic; Migraine Disorders; Patient Satisfaction; Serotonin Receptor Agonist | 2002 |
[Good ruler for assessing effectiveness. Pain free with only one tablet].
Topics: Dose-Response Relationship, Drug; Humans; Migraine Disorders; Serotonin Receptor Agonists; Treatment | 2002 |
[Controlling migraine with highly effective triptanes. Lowers rate of drug use].
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Mi | 2002 |